



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 48/00, 47/48</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/14874</b> <b>(43) International Publication Date:</b> 23 May 1996 (23.05.96)
<b>(21) International Application Number:</b> PCT/IB95/00995 <b>(22) International Filing Date:</b> 10 November 1995 (10.11.95)  <b>(30) Priority Data:</b> 08/339,245 10 November 1994 (10.11.94) US  <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 08/339,245 (CIP) Filed on 10 November 1994 (10.11.94)  <b>(71) Applicant (for all designated States except US):</b> UNIVERSITY OF MANITOBA [CA/CA]; 311 Administration Building, Winnipeg, Manitoba R3T 2N2 (CA).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SEHON, Alec [CA/CA]; 695 Academy Road, Winnipeg, Manitoba R3N 0E8 (CA). LANG, Glen, M. [CA/CA]; 14 Furness Bay, Winnipeg, Manitoba R2N 2S4 (CA).		<b>(81) Designated States:</b> AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHOD FOR GENE THERAPY INVOLVING SUPPRESSION OF AN IMMUNE RESPONSE  <b>(57) Abstract</b> <p>A method for specifically suppressing the capacity of a mammal receiving gene therapy to mount an immune response to a given expressed protein product of the deficient gene in question, which response is caused by the administration of one or more "foreign" DNA or other immunogenic therapeutic material, such as vectors used for expression of the deficient protein in the patient receiving gene therapy.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHOD FOR GENE THERAPY INVOLVING  
SUPPRESSION OF AN IMMUNE RESPONSE

This application is a continuation-in-part of pending U.S. application Serial No. 07/877,368, filed on May 4, 1992 by Lang et al., which is a continuation of abandoned U.S. application Serial No. 07/707,972, filed on May 23, 1991 by Lang et al., which is a continuation of abandoned U.S. application Serial No. 07/478,049, filed on February 2, 1990 by Lang et al., which is a continuation to abandoned U.S. application Serial No. 07/071,4621, filed on July 9, 1987 by Lang et al.

FIELD OF THE INVENTION

The present invention relates to a method for suppressing the capacity of a mammal to mount an immune response caused by the administration of one or more immunogenic therapeutic material(s), such as gene vectors or their expression proteins used in applications to gene therapy.

BACKGROUND

Foreign proteins or DNA, such as genetic material or vectors for gene therapy, or their derivatives, have therapeutic properties and are administered to patients suffering from certain diseases. However, as discussed later, the immunogenicity of the said foreign proteins, nucleotides, DNA or vectors, or of their derivatives, may vitiate the treatment and hence this invention provides an improved method for the treatment of such diseases.

Gene therapy is the insertion of a functioning gene into the cells of a patient (i) to correct an inborn

error of metabolism (i.e., genetic abnormality or birth defect resulting in the deficiency of the patient with respect to one or more essential proteins such as enzymes or hormones), or (ii) to provide a new function in a cell (Kulver, K.W., "Gene Therapy", 1994, p. xii, Mary Ann Liebert, Inc., Publishers, New York, NY).

When the host is totally deficient of the inserted gene from birth, the new protein expressed by this gene --when the latter is inserted into the appropriate cell of an adult host-- would be expected to induce in the host an immune response against itself. Hence, (i) the host would produce antibodies or cytotoxic cells to the "new" protein, and (ii) this immune response would not only combine and neutralize and thus inactivate the function of the "new" protein, but may also lead to untoward therapeutic complications due to formation of immune complexes. It is, therefore, not surprising that gene therapy has proven successful in adenosine deaminase (ADA) deficiency, i.e., in children deficient of ADA from birth, which is manifested by the absence of functional T lymphocytes and consequently to the severe combined immunodeficiency (SCID) syndrome. The reported success of gene therapy in young children deficient of ADA from birth is related to the immunodeficient status of the child, as no immune response can be generated against the foreign therapeutic genetic material. As a corollary, gene therapy would be successful if it is instituted from birth, when it is relatively easy to induce immunological tolerance to a foreign immunogenic material.

Foreign immunogenic materials, such as biologic response modifiers or their derivatives, often have therapeutic properties and are, therefore, administered to patients suffering from certain diseases. However, as a result of the immunogenicity of the foreign materials, or of their derivatives, for the reasons stated above the

insertion of the appropriate gene may vitiate the desired therapeutic effects. This invention provides a method for overcoming this inherent complication due to the immunogenic capacity of the expressed protein, and is therefore considered to represent a novel and an essential improvement for the treatment of such diseases.

As background to the present invention:

Chen, Y., Takata, M., Maiti, P.K., Mohapatra, S., Mohapatra, S.S. and Sehon, A.H., disclose that the suppressor factor of Ts cells induced by tolerogenic conjugates of OVA and mPEG is serologically and physicochemically related to the  $\alpha\beta$  heterodimer of the TCR. *J. Immunol.* 152:3-11, 1994.

Mohapatra, S., Chen, Y., Takata, M., Mohapatra, S.S. and Sehon, A.H. disclose "Analysis of TCR  $\alpha\beta$  chains of CD8<sup>+</sup> suppressor T cells induced by tolerogenic conjugates of antigen and monomethoxypolyethylene glycol: Involvement of TCR  $\alpha$ -CDR3 domain in immuno-suppression." *J. Immunol.* 151:668-698, 1993.

Bitoh, S., Takata, M., Maiti, P.K., Holford-Stevens, V., Kiersek-Jaszczuk, D. and Sehon, A.H., disclose that "Antigen-specific suppressor factors of noncytotoxic CD8<sup>+</sup> suppressor T cells downregulate antibody responses also to unrelated antigens when the latter are presented as covalently linked adducts with the specific antigen." *Cell. Immunol.* 150:168-193, 1993.

Bitoh, S., Lang, G.M., Kiersek-Jaszczuk, D., Fujimoto, S. and Sehon, A.H., disclose "Specific immunosuppression of human anti-murine antibody (HAMA) responses in hu-PBL-SCID mice." *Hum. Antibod. Hybridomas* 4:144-151, 1993.

Bitoh, S., Lang, G.M. and Sehon, A.H., disclose the "Suppression of human anti-mouse idiotypic antibody responses in hu-PBL-SCID mice." *Hum. Antibod. Hybridomas* 4:144-151, 1993.

Dreborg, S. and Akerblom, E., disclose the safety in humans of "Immunotherapy with monomethoxypolyethylene glycol modified allergens." In: S.D. Bruck (Ed.), *CRC Crit. Rev. Ther. Drug Carrier Syst.* 6:315-363, (1990).

5           Generally the term antigen refers to a substance capable of eliciting an immune response and ordinarily this is also the substance used for detection of the corresponding antibodies by one of the many in vitro and in vivo immunological procedures available for the demonstration of antigen-antibody interactions.

10           Similarly, the term allergen is used to denote an antigen having the capacity to induce and combine with reagenic (i.e., IgE) antibodies which are responsible for common allergies; however, this latter definition does not exclude the possibility that allergens may also induce reagenic antibodies, which may include immunoglobulins of classes other than IgE.

15           As used herein, the term antigenicity is defined as the ability of an antigen (immunogenic material) or allergen to combine in vivo and in vitro with the corresponding antibodies; the term allergenicity or skin activity is defined as the ability of an allergen to combine in vivo with homologous reagenic antibodies thereby triggering systemic anaphylaxis or local skin reactions, the latter reactions being the result of direct skin tests or of passive cutaneous anaphylactic (PCA) reactions; and the term immunogenicity in a general sense is the capacity of an antigen or allergen, or of their derivatives produced in vitro or processed in vivo, to induce the corresponding specific antibody response.

20           In relation to this invention, tolerogens are defined as immunosuppressive covalent conjugates consisting of an antigenic material (immunogenic proteins, etc.) and a water-soluble polymer (see e.g. Sehon, A.H., In "Progress in Allergy" (K. Ishizaka, ed.)

25           

30           

35

Vol. 32 (1982) pp. 161-202, Karger, Basel; and US patent specification No. 4261973).

5 In the present context and claims the term tolerogen thus refers to a conjugate consisting of an immunogenic material (protein or polynucleotide) and a nonimmunogenic conjugate, said tolerogen being immunosuppressive in an immunologically specific manner with respect to the antigen which is incorporated into the tolerogenic conjugate irrespective of the immunoglobulin class which  
10 is downregulated; furthermore, the tolerogen may comprise a conjugate of an essentially nonimmunogenic polymer and an immunogenic biologically active product or derivative of the genetic material used for gene therapy.

15 The therapeutic administration of foreign immunogenic material induces an immune response leading to the formation of antibodies of different immunoglobulin classes. Hence, on repeated administration, the material may form complexes in vivo with such antibodies leading to a poor therapeutic effect  
20 by virtue of its being sequestered and neutralized by the antibodies, or to anaphylactic reactions by combination with reaginic antibodies, or to other untoward conditions, i.e. immune complex diseases due to the deposition of antibody-antigen complexes in vital tissues and organs.  
25

Wilkinson et al. "Tolerogenic polyethylene glycol derivatives of xenogenic monoclonal immunoglobulins", Immunology Letters, Vol. 15 (1987) pp. 17-22, discloses the criticality of the administration time of a  
30 tolerogenic conjugate to a non-sensitized individual at least one day prior to challenge with an antigen.

The present invention overcomes deficiencies of the prior art, providing a means for inducing a priori tolerance to a protein or polynucleotide in an individual  
35 deficient of the given protein or polynucleotide, thus

making the administration of gene therapy --which involves the generation of immunogenic material in a patient deficient of the corresponding gene-- possible and effective.

5           Fig. 3 shows the effect of tolerogenic conjugates on the IgG response were the same as those used in Fig. 1. As illustrated in Fig. 3, administration of 50  $\mu$ g of OA-mPEG<sub>7,6</sub> resulted in the maximal suppression, i.e. of the order of 98% of the primary anti-OA IgG response, which  
10           was determined 14 days after the first injection of the sensitizing dose of OA by a radio-immunoassay employing the paper radio immunosorbent procedure.

#### SUMMARY OF THE INVENTION

Gene therapy procedures as currently practiced --  
15           involve the administration by itself of a foreign genetic material, or of its biologically active products-- do have certain disadvantages and limitations which are primarily due to their potential immunogenicity in the host deficient of the corresponding gene. The objectives  
20           of the present invention aim at overcoming the above mentioned complications by suppressing the production of antibodies to the foreign therapeutic genetic material and of its expression products, and of thus ensuring the efficacy of gene therapy by the prior administration of  
25           immunosuppressive doses of tolerogenic conjugates consisting of therapeutically active and potentially immunogenic materials coupled to nonimmunogenic polymers, thus overcoming or minimizing the risk of inducing anaphylactic reactions or immune complex diseases. Thus,  
30           the main objective of the invention aims at suppressing substantially an immune response to the protein resulting as a consequence of successful gene therapy, which response would undermine the therapeutic efficacy of a biologically active genetic material and which may also



cause untoward physiological reactions (e.g. anaphylaxis and/or immune complex diseases).

The invention provides a method for conducting gene therapy comprising administration to a mammal of an immunosuppressing effective amount of a tolerogenic conjugate comprising the genetic material and/or its expression product (i.e., the protein of which the patient is deficient) and monomethoxypolyethylene glycol having a molecular weight of about 500-35,000 daltons, preferably 4,500-10,000 daltons, and more preferably 3000-6000 daltons, the above administration being at prior to administration of the therapeutic genetic material for gene therapy, wherein said method results in the specific suppression of the immune response and the active development of specific tolerance to said therapeutic genetic material and/or its expression product(s). Preferably the tolerogenic conjugate is administered at least one day prior to the therapeutic genetic material.

In a preferred embodiment the therapeutic genetic material is selected from nucleotides, DNA, RNA, mRNA, attached to appropriate vectors for expression of the required therapeutic protein.

In a more preferred embodiment gene therapy vectors include Moloney murine leukemia virus vectors, adenovirus vectors with tissue specific promoters, herpes simplex vectors, vaccinia vectors, artificial chromosomes, receptor mediated gene delivery vectors, and mixtures of the above vectors.

#### BRIEF DESCRIPTION OF THE FIGURES

Figures 1, 2 and 3 show diagrams illustrating the efficiency of the invention. The percentages in brackets of Figs. 1 and 3 represent the degree of suppression with respect to the minimal immune response in animals

receiving phosphate buffered saline (PBS) in lieu of the conjugates.

Figure 1 shows the results of experiments clearly demonstrate the stringent dependency of the suppressogenicity of mPEG conjugates on their molecular composition.

Fig. 2 shows treatment with different conjugates at doses of 10  $\mu$ g and 50  $\mu$ g per mouse revealed marked differences in their suppressogenic capacity. It is also to be noted that at a dose of 150  $\mu$ g, all conjugates were highly suppressive and at 600  $\mu$ g (data not shown) all the compounds tested suppressed completely the IgE response.

#### DESCRIPTION OF THE INVENTION

The objectives of the present discovery are accomplished by a method, wherein an immunosuppressively effective amount of a tolerogen incorporating a foreign genetic material or its active derivative(s) is administered to the mammal prior to the administration of the foreign genetic material or its biologically active derivative(s). The tolerogenic conjugate is preferably administered to individuals who have not received a prior treatment with the foreign genetic material or its product, i.e. to unsensitized individuals.

The invention will provide improved methods for gene therapy of different human diseases which can be ameliorated or eliminated by the administration of the appropriate genetic materials, etc. or their therapeutic derivatives, of which the patient is deficient. The tolerogenic conjugates may be synthesized by covalent or noncovalent attachment of nonimmunogenic polymers to natural or synthetic biologically active proteins such as for example (i) murine or rat monoclonal antibodies to human T-cells which have been used to suppress transplant

rejection (Colvin, R.B. et al.; Fed. Proc. 41 (1982) p. 363, Abstr. 554) or as "miracle bullets" for the destruction of tumors (Froese, G. et al.; Immunology 45 (1982) p. 303-12, and Immunological Reviews 62 (1982), Ed. G. Möller, Munksgaard, Copenhagen), (ii) enzymes, such as superoxide dismutase (Kelly, K. et al.; Cdn. J. of Physiol. Pharmacol., 609 (1982) p. 1374-81) or L-asparaginase (Uren, J.r. et al.; Canc. Research 39 (1979) p. 1927-33), or (iii) natural or synthetic hormones.

In the presently best developed and therefore also currently best preferred mode of the invention, the tolerogen is a covalent conjugate between monomethoxypolyethylene glycol (mPEG) with molecular weight in the range of 2000-10,000 daltons and a foreign protein such as ovalbumin (OA), which served as a model protein. According to this modality, tolerogens of appropriate composition (i.e. consisting of the genetic material or its expression product and an optimal number of mPEG chains attached to it covalently) substantially suppress the formation of antibodies of different classes (e.g. IgE and IgG) which are directed specifically against the genetic material *per se* and/or against its expression product(s). The latter case is exemplified by OA or its covalent derivative with a number of 2,4-dinitrophenyl groups (DNP), i.e. OA-DNP<sub>n</sub>, where n represents the average number of DNP groups coupled per one OA molecule.

#### Animal model

The acceptability of the mouse as an experimental model for correlation to human utility in the present experiments is evidenced by Dreborg et al. "Immunotherapy with Monomethoxypolyethylene Glycol Modified Allergens". page 325, which indicates that similar results were

achieved in humans and mice and thus confirms mice are an acceptable experimental model for evaluation of mPEG-modified allergens. See also Antibodies: A Laboratory Manual, Cold Spring Harbor Press, 1988, p. 93, which indicates that laboratory mice are an acceptable experimental animal model for examining the immune response, and that mice, in particular, possess appropriate characteristics for studies of the genetics of the immune response.

10 The tolerogen employed

As water-soluble polymers to be used for the preparation of a tolerogen, polyethylene glycols, having molecular weights in the range of 2,000 to 35,000, have proved to be effective. Polyethylene glycols in this context also include physiologically acceptable derivatives thereof, such as mono-alkyl ethers, preferably the monomethyl ether, whereby the remaining single terminal hydroxyl groups of the molecules are conveniently used for coupling to the protein.

Also other water-soluble polymers (macromolecules) may be used, such as polyvinylalcohols, polyvinylpyrrolidones, polyacrylamides and homo- as well as hetero-polymers of amino acids, polysaccharides (e.g. pullulan, inulin, dextran and carboxymethyl cellulose) or physiologically acceptable derivatives of these polymers.

For the covalent coupling of such polymers to the genetic material or its antigenic expression molecules, chemical methods normally used for coupling of biologically active materials to polymers may be used. Such methods include coupling by means of mixed anhydride, cyanuric chloride, isothiocyanate, reaction between SH derivatives and  $\text{CH}_2\text{I}$  derivatives of the reacting molecules. However, it is obvious to the workers skilled in the art that other appropriate

chemical methods may be used to lead to the production of conjugates of desired compositions.

The coupling reaction is made between active groups in the antigen molecules and in the polymer molecules. If necessary such groups may have to be introduced into said molecules before the coupling reaction. Such active groups are for example  $-NH_2$ ,  $-NCS$ ,  $-SH$ ,  $-OH$ ,  $-CH_2I$  and  $COOH$  and they may be introduced according to well-known methods, if not already present in the molecules used for the production of tolerogenic conjugates.

In order to minimize the liberation *in vivo* of the immunogenic and/or allergenic constituent(s) of the tolerogenic conjugates and to maximize their effectiveness at a low dose, it is desirable that the covalent link between the water-soluble polymer and protein or its active derivative(s) should be as stable as possible under physiological conditions.

The coupling of the polymer onto the antigenic or genetic material must, as mentioned above, have been carried out to such an extent that the conjugate is rendered tolerogenic, as well as substantially non-allergenic and substantially non-immunogenic. In other words the tolerogens must retain a certain number of epitopes of the unmodified antigen, as long as their immunogenicity has been decreased to that they do not induce the formation of antibodies which may cause unacceptable adverse reactions.

To achieve tolerogenicity, the degree of substitution, also referred to as the degree of conjugation, which is defined as the number of polymer molecules coupled per antigen molecule, varies from one antigen molecule to another depending on the nature and size of the antigen and on the polymer and its molecular weight. Therefore, for the synthesis of a tolerogenic conjugate of a given antigen it is essential to

synthesize a series of conjugates with different degrees of substitution and then establish the special range wherein the above mentioned requirements are fulfilled. Too low a degree of substitution may result in conjugates still endowed with allergenic and immunogenic properties, and too high a degree of substitution may result in conjugates which are not tolerogenic. One of skill in the relevant art will be able to optimize the degree of substitution using the disclosure as example. The optional substitution range is one in which tolerogenicity is achieved. One of skill in the art can perform the steps outlined in the specification and arrive at the appropriate degree of coupling of the nonimmunogenic polymer onto the antigenic protein so as to achieve the claimed properties. In a preferred embodiment, a ratio of 2-12 mPEG per antigenic protein is preferred (see Tables 5-7).

In view of the finely tuned homeostatic balance of the immune response, which may be easily perturbed either upwards or downwards by the administration of a given antigen depending on its dose, state of aggregation and route of administration, as well as the presence or absence of adjuvants, it is critical when practicing the invention for treatment of appropriate disease conditions, that the tolerogenic conjugates be administered in such a manner as to lead to the down-regulation of the immune response with respect to one or more classes of immunoglobulins directed against the unconjugated biologically active product of the genetic material. Hence, in practicing this invention for treatment of appropriate diseases, the tolerogenic conjugates are to be injected in absence of adjuvants since the adjuvants may counteract their suppressogenic effects. However, the inclusion of adjuvants along with the unconjugated immunogenic material in the examples

given below was justified so as to stimulate in experimental animals the enhanced production of antibodies in a relatively short time and to thus test under more stringent conditions the capacity of the tolerogenic conjugates to suppress the immune response in these animals even under these extreme conditions which are particularly favorable for enhancing the immune response.

The foreign genetic material or vehicle

In the claims and in the specifications, proteins and polypeptides are used synonymously. In the present context and claims the term foreign genetic material refers to a nucleotide, DNA, RNA, mRNA, plasmid, which are used as carriers of the gene and/or the gene itself responsible for the expression of the appropriate protein or protein derivative (fragments included), which are substantially immunogenic in the animal to be treated. The term biologically active antigenic protein as used herein includes preproteins, protein fragments, and gene fragments which express active proteins.

According to one aspect of the invention the genetic material should be therapeutically effective. Many such proteins, vectors, DNA are known per se (Culver, K.W., "Gene Therapy", 1994, p. xii, Mary Ann Liebert, Inc., Publishers, New York, NY, incorporated herein by reference in its entirety). For the purposes of example only, vectors may be selected from the group consisting of Moloney murine leukemia virus vectors, adenovirus vectors with tissue specific promoters, herpes simplex vectors, vaccinia vectors, artificial chromosomes, receptor mediated gene delivery, and mixtures of the above vectors. Gene therapy vectors are commercially available from different laboratories such as Chiron, Inc., Emeryville, California; Genetic Therapy, Inc.,

Gaithersburg, Maryland; Genzyme, Cambridge, Massachusetts; Somatx, Alameda, California; Targeted Genetics, Seattle, Washington; Viagene and Vical, San Diego, California.

5           The effective doses (amounts) and formulations commonly used are also known and may be applied to the present invention, although the invention potentially may employ reduced or increased doses. In principle, both the biologically active foreign genetic material or its  
10           derivatives, as well as the corresponding tolerogenic conjugates, may be administered parenterally in a soluble form in isotonic solution and after removal of aggregates by centrifugation. Moreover, to destroy  
15           unwanted cells, such as cancer cells or the host's cytotoxic cells responsible for auto-immune diseases, one may insert genetic material consisting in tandem of the DNA specific for the carrier of the bullet (e.g., an antibody molecule directed to a cell marker) and the DNA representing the bullet (e.g., toxins represented by  
20           ribosome inactivating proteins) into the patient.

#### Time intervals for the administration

          For the induction of immunological tolerance to a given protein the protocol followed according to the invention comprises the administration initially of an  
25           immunosuppressively effective dose (amount) of tolerogen, which is given prior to the administration of the therapeutically active protein or its product. If necessary, this dose may be portioned and given on repeated occasions. The immunosuppressive dose which is  
30           given may vary from tolerogen to tolerogen, but it has to be administered prior to the entry of the protein into the host's system. According to the principles outlined in the examples, the practitioner skilled in the art can determine the variables such as dose of tolerogen and the



minimum interval of time between its administration and the appearance of the immunogenic protein in the host's system. See, for example, references discussed in background of the invention. However, it is to be expected that gene therapy, resulting in the production of a "new" protein in the protein-deficient patient, has to be preceded by administration of the specific tolerogenic conjugate, i.e., the conjugate comprising the same protein and capable of suppressing selectively the immune response of the host with respect to the protein in question.

Generally the tolerogenic conjugate may be administered at any time prior to the administration of the foreign antigenic protein or genetic material. A ~~the~~ period of at least one day prior to the administration of the foreign genetic material is preferred. In a more preferred embodiment, the tolerogenic conjugate is administered at least seven days prior to administration of the foreign genetic material. The immunosuppressive dose refers to the amount of tolerogen required to substantially reduce the immune response of the patient to the protein or to its derivative(s) which will be produced as a result of the gene therapy. According to one mode of the invention, further doses of the tolerogen may be given in conjunction with the protein or its derivative(s), i.e. after the primary administration of the tolerogen. This mode may represent one way of sustaining the suppression and may offer a more efficient therapeutic regimen for the disease condition for which the treatment has been designed.

The invention will now be illustrated by some non-limiting examples wherein OA and its tolerogenic mPEG derivatives have been applied as model substances to confirm the usefulness of the proposed immunosuppressive treatment of a well-established animal model commonly

utilized in the field of immunology. The conjugates will be designated as OA-(mPEG)<sub>n</sub> where n represents the average degree of conjugation.

#### EXAMPLE 1

##### 5     Preparation of OA-mPEG conjugates having different degrees of substitution

10     The conjugates used in the experiments given below have been prepared by coupling mPEG molecules to OA essentially according to the procedure described by Abuchowski et al. (J. Biol. Chem. 252, 3518, 1977) utilizing cyanuric chloride as one of the possible coupling agents. To begin with, in the experiment described the "active intermediate" consisting of an mPEG molecule attached to cyanuric chloride was prepared.

15     It was found that the most important condition of this reaction was that all reagents be completely anhydrous and that the reaction mixture be protected from atmospheric moisture because of its high susceptibility to hydrolysis. Among various methods used for the synthesis of the "active intermediate", the example given below illustrates the general procedure. (See also Jackson, C. -J.C., Charlton, J.L., Kuzminski, K., Lang, G.M. and Sehon, A.H. "Synthesis, isolation and characterization of conjugates of ovalbumin with monomethoxypolyethylene glycol using cyanuric chloride as the coupling agent. Anal. Biochem. 165: 114, 1987, incorporated herein by reference in its entirety.)

25     Monomethoxypolyethylene glycol (2.5 g. mol wt 5590, Union Carbide) was dissolved with warming in anhydrous benzene (40 ml) and a portion of the benzene (20 ml) was removed by distillation to azeotrope off any water in the polymer. Cyanuric chloride [(CNCl)<sub>3</sub>, 0.83 g, Aldrich, recrystallized from benzene] was added under nitrogen followed by potassium carbonate (0.5 g. anhydrous

30

powdered) and the mixture stirred at room temperature for 15 hours. The mixture was then filtered under dry nitrogen and the filtrate mixed with anhydrous petroleum ether (ca 50 ml, b.pt. 30-60°C) in order to precipitate the polymer. The polymer was separated by filtration under nitrogen, dissolved in benzene (20 ml) and reprecipitated with petroleum ether. This process was repeated seven times to insure that the polymer was free of any residual cyanuric chloride. The active intermediate was finally dissolved in benzene, the solution frozen and the benzene sublimed away under high vacuum to leave a fine white powder.

Elemental analysis of the intermediate confirmed that it contained 2 chlorine atoms. The intermediate, corresponding to  $C_{256.3}H_{307.7}O_{127.2}N_3Cl_2$  with an average molecular weight of 5,738 daltons would have a theoretical composition in percentages of C, 53.65; H, 8.92; N, 0.73; Cl, 1.24; which agrees with its determined composition of C, 53.51; H, 8.89; N, 0.77; Cl, 1.08.

The chloride content of the intermediate was also determined by hydrolysis and titration of the chloride released with silver nitrate. Thus, the activated intermediate (120 mg) was dissolved in water (10 ml) and the pH adjusted to 10 with dilute sodium hydroxide. After heating at 90°C for two hours, the solution was cooled and the chloride titrated with silver nitrate (0.001N), using a chloride ion selective electrode to indicate the endpoint. The chloride content of the activated intermediate was found to be 2.1, consistent with the structure shown above.

The OA [40 mg, purified by chromatography on Ultrogel® ACA-54 (LKB, Bromma, Sweden)] was dissolved in sodium tetraborate buffer (4 ml, 0.1 M, pH 9.2) and the activated mPEG added to the solution at 4°C. The amount of activated mPEG was varied to prepare conjugates of

differing degrees of polymer substitution. Mole ratios (mPEG/OA) used to prepare specific conjugates are given in Table 1. The polymer-protein mixture was stirred for one half hour at 4°C and then one half hour at room temperature. The reaction mixture was desalted by either dialyzing for four days against running distilled water or by passing through a column of Sephadex® G-25 (Pharmacia Fine Chemicals AB, Uppsala, Sweden).

A DEAE-cellulose or DEAE-Sephacryl® (Pharmacia Fine Chemicals AB, Uppsala, Sweden) column (5 cm by 30 cm) was equilibrated with phosphate buffer (0.008 M, pH 7.7). The salt free OA conjugates were applied in water and the free (unbound) mPEG washed through the column with the pH 7.7 buffer. Free mPEG was detected on thin layer chromatography [Camag (Kieselgel DSF-5, Terochem Lab Ltd, Alberta) eluant 3:1 chloroform/methanol] using iodine vapor for development. After removal of the free mPEG from the ion-exchange column, sodium acetate buffer (0.05 M, pH 4.0) was used to elute the conjugate. The conjugate fractions were dialyzed and lyophilized to give the dry conjugates.

Table 1

Preparation of OA-mPEG <sub>n</sub> Conjugates			
Conjugates <sup>a</sup>	Preparation ratio <sup>b</sup>	% mPEG <sup>c,e</sup>	%OA <sup>d,e</sup>
OA-mPEG <sub>3.2</sub>	10:1	26	70
OA-mPEG <sub>6.6</sub>	25:1	36	47
OA-mPEG <sub>7.6</sub>	25:1	42	47
OA-mPEG <sub>10.6</sub>	50:1	51	41
OA-mPEG <sub>11.9</sub>	50:1	52.4	38

<sup>a</sup> The degree of substitution, *n*, is calculated by the formula

$$5 \quad \frac{\% \text{ mPEG}}{\% \text{ OA}} \times \frac{\text{mol wt OA}}{\text{mol wt mPEG}}$$

<sup>b</sup> Mole ratio mPEG:OA based on a molecular weight of 5.740 for mPEG-dichlorocyanurate and 44.460 daltons for OA.

10 <sup>c</sup> The percentages of mPEG by weight were determined by nuclear magnetic resonance (NMR).

<sup>d</sup> The percentages of protein by weight were determined by the biuret method.

15 <sup>e</sup> The total compositions of the conjugates, as calculated from the NMR and biuret analysis, are only of the order of 90% of the samples by weight; the difference of the order of 10% is attributed to moisture absorbed by the conjugates and/or to small amounts of DEAE-cellulose leaching from the column.

#### EXAMPLE 2

#### 20 Determination of the immunosuppressive effect on the IgE response of different OA-mPEG<sub>n</sub> conjugates

The results of experiments illustrated in Fig. 1 clearly demonstrate the stringent dependency of the suppressogenicity of mPEG conjugates on their molecular composition. Thus, whereas treatment of groups of four  
25 (B6D2)F1 mice each with 50 µg of OA-mPEG<sub>3,2</sub>, or OA-mPEG<sub>6,6</sub>, or OA-mPEG<sub>7,6</sub> one day prior to intraperitoneal immunization with the sensitizing dose, consisting of 1µg of OA and 1 mg Al(OH)<sub>3</sub>, led to essentially complete (99-  
30 100%) abrogation of the primary anti-OA IgE response, as measured --on day 14 after immunization-- by PCA in hooded rats, the more substituted conjugates, i.e. OA-mPEG<sub>10,6</sub> and OA-mPEG<sub>11,9</sub>, inhibited the anti-OA IgE response, respectively, only to the extent of 94% and

50%. In this and the following examples, the weights of the conjugates given correspond to their protein content.

### EXAMPLE 3

5 Long lasting suppression of the IgE response by protein-mPEG conjugates in contrast to a transient suppressive effect of unconjugated protein

It is to be noted that even unmodified OA was capable of downregulating the primary IgE response in relation to the response of control mice which had received PBS instead of OA or conjugates. In this experiment three groups of four (B6D2)F1 mice each received phosphate buffered saline, or 50 µg of OA-mPEG<sub>4.5</sub> or 50 µg of OA. All animals were bled on day 10, 14, 21, 27, 35, 42 and 49 and their IgE titers were determined by PCA in hooded rats. As illustrated in Table 2, it is important to point out that whereas the suppressogenic effect of OA-mPEG conjugates was long-lasting, the down-regulating effect of free OA was of short duration and, in actual fact, its administration predisposed the animals to an anamnestic response which reached, after booster immunization (administered on day 28), IgE antibody levels equivalent to those of control animals which had received PBS and the two sensitizing doses of one antigen. The results given in Table 2 clearly demonstrate that a tolerogenic conjugate injected prior to repeated administration of the corresponding free protein essentially abrogated the immune response.

Table 2

Effect of administering 50  $\mu$ g of OA-mPEG<sub>4,5</sub> or of free OA one day prior to immunization

5	Day of bleeding after <u>primary immunization</u>	PCA titers for groups of <u>mice treated with</u>		
		<u>PBS</u>	<u>OA</u>	<u>OA-mPEG<sub>4,5</sub></u>
	10	5,120	40	< 4
	14	1,940	40	< 4
10	21	1,280	40	< 4
	27	640	40	< 4
	35	1,920	1,920	160
	42	2,560	1,280	160
	49	5,120	N.D.*	160
15	On day 28 all three groups received a booster dose of the sensitizing OA preparation.			

\* N.D. = not determined

#### EXAMPLE 4

#### The effect of different doses of the tolerogen on the IgE response

Each OA-mPEG conjugate was injected into groups of 4 mice each at the four doses of 10  $\mu$ g, 50  $\mu$ g, 150  $\mu$ g and 600  $\mu$ g. The control group of mice received PBS as placebo.

As is evident from Fig. 2, treatment with different conjugates at doses of 10  $\mu$ g and 50  $\mu$ g per mouse revealed marked differences in their suppressogenic capacity. It is also to be noted that at a dose of 150  $\mu$ g, all conjugates were highly suppressive and at 600  $\mu$ g (data not shown) all the compounds tested suppressed completely the IgE response.

EXAMPLE 5The effect of different doses of the tolerogen on the IgE response

5 The sera used in Fig. 3 to illustrate the effect of tolerogenic conjugates on the IgG response were the same as those used in Fig. 1. As illustrated in Fig. 3, administration of 50  $\mu$ g of OA-mPEG<sub>7,6</sub> resulted in the maximal suppression, i.e. of the order of 98% of the primary anti-OA IgG response, which was determined 14  
10 days after the first injection of the sensitizing dose of OA by a radio-immunoassay employing the paper radio immunosorbent procedure (Kelly, K.A. et al.; J. Immunol. Meth. 39 (1980) p. 317-33) utilizing OA bound to the paper and with <sup>125</sup>I-labelled affinity purified sheep  
15 antiserum to mouse IgG.

EXAMPLE 6

The suppressive effect of OA-mPEG<sub>10</sub> on IgM, IgG, and IgE plaque forming cells (PFC) in spleen and lymph nodes.

20 One mg of OA-mPEG<sub>10</sub> (containing 10 mPEG groups with an average mol wt of 10,000 daltons, which were coupled per OA molecule by the succinic anhydride method (Wie, S.I. et al., Int. Archs. Allergy appl. Immun. 64, 84 (1981)) or PBS was administered intraperitoneally to each group of four (B6D2)F1 mice each one day prior to  
25 immunization with 1  $\mu$ g of DNP<sub>3</sub>-OA in 1 mg Al(OH)<sub>3</sub>.

On several days thereafter the spleen, as well as the mesenteric, parathymic and inguinal lymph nodes were removed and assayed for IgM, IgG, and IgE anti-DNP PFC (Rector, E.S. et al., Eur. J. Immunol. 10, p. 944-49  
30 (1980). In Table 3 are given the numbers of PFC in the above tissues 10 days after immunization; from these data it is evident that treatment with this tolerogen markedly reduced the number of IgM, IgE, and IgG PFC in all tissues examined. Therefore, these results support the



claim that the tolerogens shut off the immune response rather than neutralize the circulating antibodies.

Table 3

The effect of OA-mPEG<sub>10</sub> on the suppression of IgM, IgG, and IgE plaque forming cells (PFC) in spleen and lymph nodes

		Anti-DNP PFC per 10 <sup>8</sup> cells from different tissues*			
Antibody Class	Treatment	Spleen	Parathymic Nodes	Mesenteric Nodes	Inguinal Nodes
10 IgM	PBS	2,150	2,950	Nd	Nd **
	OA-mPEG	900	200	Nd	Nd
IgG	PBS	15,350	78,550	5,000	Nd
	OA-mPEG	Nd	1,300	Nd	Nd
15 IgE	PBS	10,410	16,530	11,140	300
	OA-mPEG	500	950	400	Nd

\* Each tissue sampling represents a pool from 4 mice

\*\* Nd = undetected

The above experiments establish the immuno-suppressive effects discussed above and the effects at the various dosages.

#### EXAMPLE 7

In addition, utilizing the hu-PBL-SCID mice, it was demonstrated that in accordance with the phenomenon of "linked immunological suppression", cross-specific suppression of the human antibody response could be induced to murine mAbs which differ in their antigen binding specificities from those of the murine mAbs which had been incorporated into the tolerogenic conjugates, on condition that both mAbs shared the same heavy and light chains. Thus, that pan-specific suppression of the "human" antibody responses against murine monoclonal antibodies (i.e., HAMA responses) of the IgG class could be achieved with 8 tolerogenic mPEG preparations, each consisting of one of the 4 gamma chains and of one of the

two types of light chains of murine IgG (Bitoh, S., Lang, G.M., Kierek-Jaszczuk, D., Fujimoto, S. and Schon, A.H. Specific immunosuppression of human anti-murine antibody (HAMA) responses in hu-PBL-SCID mice. Hum. Antibod. Hybridomas 4:144-151, 1993).

The utility of this technology for therapeutic strategies in man, which necessitate the administration of immunogenic Biological Response Modifiers (BRMs), is apparent.

The safety of administration of mPEG conjugates of different allergenic proteins has been established in clinical trials in a number of countries in close to 300 patients afflicted by a variety of allergies medicated by IgE antibodies (Dreborg, S. and Akerblom, E. Immunotherapy with monomethoxypolyethylene glycol modified allergens. In: S.D. Bruck (Ed.), CRC Crit. Rev. Ther. Drug Carrier Syst. 6:315-363, (1990)).

It is to be emphasized that the function of the mPEGylated protein in the present strategy is to induce Suppressor T (Ts) cells which recognize the epitopes shared by both the unmodified and the mPEGylated BRM. In other words, this technology leads to conversion of antigens not only to nonimmunogenic, but most importantly to actively immunosuppressive molecules, which induce immunologic tolerance with respect to the original unmodified protein antigen. By contrast, the purpose of some other workers and companies utilizing mPEG conjugates of BRMs is to only reduce their immunogenicity i.e., without converting them to active tolerogens, and to thus only increase their half-life in circulation.

The discovery that pretreatment of a host with tolerogenic mPEG conjugates of a given protein Ag, followed by administration of the unmodified Ag, results in abrogation of the host's capacity to mount an antibody response to the Ag in question has a direct utility in

some forms of "gene therapy" which would result in the production of the protein corresponding to the gene in question, on condition that the host would have been deficient of the gene responsible for the expression of the particular protein from birth (see, Sehon, A.H. Suppression of antibody responses by chemically modified antigens, Carl Prausnitz Memorial Lecture, XVIII Symposium Collegium Internationale Allergologicum, Int. Arch. Allergy appl. Immunol. 94:11-20, 1991; Takata, M., Maiti, P.K., Kubo, R.T., Chen, Y-H. Holford-Stevens, V., Rector, E.S. and Sehon, A.H. Cloned suppressor T cells derived from mice tolerized with conjugates of antigen and monomethoxypolyethylene glycol. *J. Immunol.* 145:2846-2853, 1990; and Takata, M., Maiti, P.K., Bitoh, S., Holford-Stevens, V., Kierek-Jaszczuk, D., Chen, Y., Lang, G.M. and Sehon, A.H. Downregulation of helper T cells by an antigen-specific monoclonal Ts factor. *Cell. Immunol.* 137:139-149, 1991).

On the basis of well known immunological principles, it would be obvious that in conditions when the host is totally deficient, from birth, of the gene which has to be inserted after the maturation of the immune system, the protein expressed by the gene in question induces in the host an immune response against itself, (since the host with a normal immune system would not have been rendered from birth tolerant to the protein in question). Thus, (i) the immune response of the host to this protein would be manifested in the production of antibodies or cytotoxic cells by the host to the "new" protein, and (ii) this immune response would not only neutralize the "new" protein, but may also lead to diverse therapeutic complications due to formation of "immune complexes" consisting of the resulting antibody-antigen aggregates.

Clearly, the one condition for which gene therapy has proven to be an effective therapeutic modality is

adenosine deaminase (ADA) deficiency, which results in the impairment of T lymphocytes and hence in the severe combined immunodeficiency disorder (SCID) in children deficient of ADA from birth. Therefore, it is not  
5 surprising that Dr. Culver was successful in developing a curative gene therapy for this condition by treating the SCID kids by infusion of their own "ADA gene-corrected cells".

However, unless gene therapy is instituted from  
10 birth, when it is relatively easier to induce immunological tolerance to a foreign genetic material or its expressed products, than in adulthood after maturation of the immune system, the success of gene therapy in hosts with a well formed immune system would  
15 be undermined by the above-mentioned complications. Hence, to avoid these complications, the induction of immunological tolerance to a well-defined protein Ag, by pretreatment of the host with tolerogenic mPEG conjugates of the corresponding Ag, i.e.,  $\text{Ag(mPEG)}_n$ , is indispen-  
20 sable for the success of gene therapy in disease conditions, when the same protein is expressed by the inserted gene, since this protein would induce deleterious immune response against itself in the host.

The present invention is the confirmation and  
25 extension of the earlier discovery of induction of immunological tolerance by immunosuppressive  $\text{Ag(mPEG)}_n$  conjugates to therapies involving the insertion of new genes into the host with an intact immune system.

#### EXAMPLE 8

30 Thus, in accordance with the present invention, prior to beginning of gene therapy, i.e., prior to insertion of a new gene into a host which is required for expression of a protein beneficial to the host, e.g., one of the deficient clotting factors or enzymes, it is essential to

render the host tolerant to the protein in question by the use of the invention described.

#### EXAMPLE 9

5 The expressed protein material of the cystic fibrosis transmembrane conductance regulatory gene (CFTR) (Genzyme, Cambridge, Massachusetts) for the treatment of cystic fibrosis is dissolved in sodium tetraborate buffer (4 ml, 0.1 M, pH 9.2) and the activated mPEG added to the solution at 4°C. The amount of activated mPEG is varied  
10 to prepare conjugates of differing degrees of polymer substitution. Different mole ratios (mPEG/gene product) are used to prepare specific tolerogenic conjugates as described earlier. The polymer-gene product mixture is stirred for one half hour at 4°C and then one half hour  
15 at room temperature. The reaction mixture is desalted by either dialyzing for four days against running distilled water or by passing through a column of Sephadex® G-25 (Pharmacia Fine Chemicals AB, Uppsala, Sweden).

A DEAE-cellulose or DEAE-Sephacryl® (Pharmacia Fine  
20 Chemicals AB, Uppsala, Sweden) column (5 cm by 30 cm) is equilibrated with phosphate buffer (0.008 M, pH 7.7). The salt free mPEG conjugates of the cystic fibrosis gene product are applied in water and the free (unbound) mPEG washed through the column with the pH 7.7 buffer. Free  
25 mPEG is detected on thin layer chromatography [Camag (Kieselgel DSF-5, Terochem Lab Ltd, Alberta) eluant 3:1 chloroform/methanol] using iodine vapor for development. After removal of the free mPEG from the ion-exchange column, sodium acetate buffer (0.05 M, pH 4.0) is used to  
30 elute the conjugate. The conjugate fractions are dialyzed and lyophilized to give the dry conjugates.

Conjugates of the CFTR gene are administered to a patient at least one day prior to transfer of the cystic fibrosis transmembrane conductance regulator gene to lung

tissue using recombinant adenoviral vectors or liposomes.

#### EXAMPLE 10

The expressed protein material of the low density lipoprotein receptor (LDLr) gene used in the treatment of familial hypercholesterolemia is dissolved in sodium tetraborate buffer (4 ml, 0.1 M, pH 9.2) and the activated mPEG added to the solution at 4°C. The amount of activated mPEG is varied to prepare conjugates of differing degrees of polymer substitution. Different mole ratios (mPEG/gene product) is used to prepare specific tolerogenic conjugates as described earlier. The polymer-gene product mixture is stirred for one half hour at 4°C and then one half hour at room temperature. The reaction mixture is desalted by either dialyzing for four days against running distilled water or by passing through a column of Sephadex® G-25 (Pharmacia Fine Chemicals AB, Uppsala, Sweden).

A DEAE-cellulose or DEAE-Sephacryl® (Pharmacia Fine Chemicals AB, Uppsala, Sweden) column (5 cm by 30 cm) is equilibrated with phosphate buffer (0.008 M, pH 7.7). The salt free mPEG conjugates of the LDLr-gene products are applied in water and the free (unbound) mPEG washed through the column with the pH 7.7 buffer. Free mPEG is detected on thin layer chromatography [Camag (Kieselgel DSF-5, Terochem Lab Ltd, Alberta) eluant 3:1 chloroform/methanol] using iodine vapor for development. After removal of the free mPEG from the ion-exchange column, sodium acetate buffer (0.05 M, pH 4.0) is used to elute the conjugate. The conjugate fractions are dialyzed and lyophilized to give the dry conjugates.

Conjugates of the LDLr gene product are administered to a patient. Hepatocytes are grown in the laboratory and genetically altered with a murine retroviral vector containing LDLr gene. The cells are reinfused through

the hepatic artery to the liver of the patient at least one day after administration of the conjugate.

TABLE 4

DEPENDENCE OF IMMUNOSUPPRESSIVE EFFECTIVENESS OF PROTEIN  
(mPEG)<sub>n</sub> CONJUGATES ON THE AVERAGE DEGREE OF CONJUGATION  
(n) \*

TABLE 4: SUPPRESSION OF ANTIBODIES TO OVALBUMIN (OVA)

Conjugate **	Degrees of Suppression of the Anti-OVA Antibody Responses Compared to Responses in Control Mice Which Had Received Saline in lieu of the Conjugate***	
	IgE antibody	IgG1 antibody
OVA (mPEG) <sub>1.2</sub>	99%	86%
OVA (mPEG) <sub>6.6</sub>	100%	91%
OVA (mPEG) <sub>7.6</sub>	100%	98%
OVA (mPEG) <sub>10.6</sub>	94%	90%
OVA (mPEG) <sub>11.9</sub>	50%	86%

\* The value of n for each conjugate was calculated by dividing the micromoles of mPEG (determined by NMR) by the micromoles of protein (determined by the Biuret assay).

\*\* A single dose of 50 µg (with respect to protein content of each conjugate) was administered into mice seven days prior to immunization with OVA.

\*\*\* The degrees of suppression for IgE and IgG antibodies were calculated, respectively, by the formulae:

$$\left[ 1 - \frac{\text{mean of PCA titers of test group}}{\text{mean of PCA titers of control group}} \right] \times 100\%$$

$$\left[ 1 - \frac{\text{mean of ELISA titers of test group}}{\text{mean of ELISA titers of control group}} \right] \times 100\%$$

\*\*\*\* The molecular weight of the mPEG used for this conjugation was 6200 daltons.

\*\*\*\*\*From Table 4 it can be seen that ratios of mPEG of 3.2, 6.6, 7.6, 10.6 and 11.9 to one antigenic protein, for example OVA, are preferred.

TABLE 5

TABLE 5: SUPPRESSION ANTIBODIES TO SAPORIN (SAP)

Conjugate*	Degrees of Suppression of the Anti-SAP Antibody Responses**	
	IgE antibody	IgG1 antibody
SAP (mPEG) <sub>6</sub>	100%	94%
SAP (mPEG) <sub>7</sub>	100%	96%
SAP (mPEG) <sub>11</sub>	100%	99%

\* A single dose of 100 µg (with respect to protein content of each conjugate) was administered into mice seven days prior to immunization with SAP.

\*\* Please see explanatory notes in footnote "\*\*\*\*" to Table 4.

\*\*\* The molecular weight of the mPEG used for this conjugation was 3000 daltons. From Table 5 it can be seen that ratios of mPEG of 6, 7 and 11 to one antigenic protein, for example SAP, are preferred.



TABLE 6TABLE 6: SUPPRESSION OF ANTIBODIES TO HUMANIZED MURINE IgG (H<sub>m</sub>IgG)

Conjugate*	Percent Suppression of the IgG1 Anti-H <sub>m</sub> IgG antibody responses**
HmIgG (mPEG) <sub>32</sub>	91%
HmIgG (mPEG) <sub>36</sub>	94%
HmIgG (mPEG) <sub>39</sub>	98%
HmIgG (mPEG) <sub>40</sub>	98%
HmIgG (mPEG) <sub>41</sub>	97%

\* A single dose of 200 µg (with respect to protein content of each conjugate) was administered into rats seven days prior to immunization with H<sub>m</sub>IgG.

\*\* Please see explanatory notes in footnote "\*\*\*\*" to Table 5.

\*\*\* The molecular weight of the mPEG used for this conjugation was 3000 daltons.

\*\*\*\*From Table 6 it can be seen that ratios of mPEG of 32, 36, 39, 40, and 41 to one antigenic protein, for example IgG, are preferred.

Table 7 shows a list of gene therapy systems which have been approved by the Recombinant DNA Activities Committee of the National Institutes of Health. However, no consideration appears to have been given to overcoming the potential complications due to the host mounting an immune response against the respective gene products. Clearly, if the patient had been producing from birth these proteins, he/she would be tolerant to them, i.e., and gene therapy would not necessitate the strategy of the described invention if the patient has retained his/her tolerance between the shutting off of his/her own genes producing the desired protein and the time of initiation of gene therapy by transfer of the gene in association with an appropriate "vehicle" for the renewed production of the protein. The table also shows a list of health disorders for which chromosomal locations are known which are considered treatable by gene therapy.

<i>Disorder (gene used)</i>	<i>Cells altered (vector)</i>
Adenosine deaminase deficiency <sup>a</sup> (ADA)	T-cells and stem cells (retroviral)
Brain tumors (MDR-1)	Stem cells (retroviral)
Brain tumors (primary and metastatic) (HS-tk)	Tumor cells (retroviral)
Brain tumors (primary) <sup>a</sup> (HS-tk)	Tumor cells (retroviral)
Brain tumors (primary and metastatic) (HS-tk)	Tumor cells (retroviral)
Brain tumors (primary and metastatic) (HS-tk)	Tumor cells (retroviral)
Brain tumors (primary) (anti-sense IGF-1)	Tumor cells (DNA transfection)
Brain tumors (primary) <sup>a</sup> (HS-tk)	Tumor cells (retroviral)
Brain tumors (primary and metastatic) (HS-tk)	Tumor cells (retroviral)
Breast cancer (IL-4)	Fibroblasts (retroviral)
Breast cancer (MDR-1)	Stem cells (retroviral)
Breast cancer (MDR-1)	Stem cells (retroviral)
Colorectal cancer (IL-4)	Fibroblasts (retroviral)
Colorectal cancer (IL-2 or TNF- $\alpha$ gene)	Tumor cells (retroviral)
Colorectal cancer (HLA-B7 and $\beta$ 2-microglobulin)	Tumors cells (liposomes)
Colorectal cancer (IL-2)	Fibroblasts (retroviral)
Cystic fibrosis <sup>a</sup> (CF TR)	Respiratory epithelium (adenoviral)
Cystic fibrosis <sup>a</sup> (CF TR)	Respiratory epithelium (adenoviral)
Cystic fibrosis (CF TR)	Respiratory epithelium (liposomes)

<i>Disorder (gene used)</i>	<i>Cells altered (vector)</i>
Cystic fibrosis <sup>a</sup> (CF TR)	Respiratory epithelium (adenoviral)
Cystic fibrosis <sup>a</sup> (CF TR)	Respiratory epithelium (adenoviral)
Cystic fibrosis <sup>a</sup> (CF TR)	Respiratory epithelium (adenoviral)
Familial hypercholesterolemia <sup>a</sup> (LDLr)	Liver cells (retroviral)
Gaucher disease <sup>a</sup> (glucocerebrosidase)	Stem cells (retroviral)
Gaucher disease <sup>a</sup> (glucocerebrosidase)	Stem cells (retroviral)
Gaucher disease <sup>a</sup> (glucocerebrosidase)	Stem cells (retroviral)
Gaucher disease (glucocerebrosidase)	Stem cells (retroviral)
HIV infection (Mutant Rev)	T cells (retroviral)
HIV infection (HIV-1 III env)	Muscle (retroviral)
HIV infection (HIV-1 IIIB Env and Rev)	Muscle (retroviral)
HIV infection (HIV-1 ribozyme)	T cells (retroviral)
Leptomeningeal carcinomatosis (HS-tk)	Tumor cells (retroviral)
Malignant melanoma (IL-4)	Tumor cells (retroviral)
Malignant melanoma (IL-2)	Tumor cells (retroviral)
Malignant melanoma (IL-2)	Tumor cells (retroviral)
Malignant melanoma (IL-2)	Tumor cells (retroviral)
Malignant melanoma (IL-4)	Fibroblasts (retroviral)
Malignant melanoma (HLA-B7)	Tumor cells (liposomes)

<i>Disorder (gene used)</i>	<i>Cells altered (vector)</i>
Malignant melanoma (HLA-B7 and $\beta_2$ -microglobulin)	Tumor cells (liposomes)
Malignant melanoma (TNF- $\alpha$ or IL-2)	T cells or tumor cells (retroviral)
Malignant melanoma (interferon- $\gamma$ )	Tumor cells (retroviral)
Malignant melanoma (B7)	Tumor cells (retroviral)
Neuroblastoma <sup>a</sup> (IL-2)	Tumor cells (retroviral)
Non-small cell lung cancer (p53 or antisense K-ras)	Tumor cells (retroviral)
Ovarian cancer (HS-tk)	Tumor cells (retroviral)
Ovarian cancer (MDR-1)	Stem cells (retroviral)
Ovarian cancer (MDR-1)	Stem cells (retroviral)
Renal cell carcinoma (IL-2)	Tumor cells (retroviral)
Renal cell carcinoma (IL-4)	Fibroblasts (retroviral)
Renal cell carcinoma (TNF- $\alpha$ or IL-2)	Fibroblasts (retroviral)
Renal cell carcinoma (GM-CSF)	Tumor cells (retroviral)
Small cell lung cancer (IL-2)	Tumor cells (DNA transfection)
Solid tumors (HLA-B7 and $\beta_2$ -microglobulin)	Tumor cells (liposomes)

Disorder	Location	Disorder	Location
<b>A</b> 11-Beta-hydroxysteroid dehydrogenase deficiency (1)	Chr.1	[AMP deaminase deficiency, erythrocyte] (1)	1p21-p13
3-Beta-hydroxysteroid dehydrogenase, type II, deficiency (3)	1p13.1	Amyloid neuropathy, familial, several allelic types (1)	18q11.2-q12.1
3-Hydroxyacyl-CoA dehydrogenase deficiency (1)	Chr.7	Amyloidosis, cerebroarterial, Dutch type (1)	21q21.3-q22.05
3-Ketothiolase deficiency (1)	11q22.3-q23.1	Amyloidosis, Finnish type, 105120 (1)	9q34
Aarskog-Scott syndrome (2)	Xp11.21	Amyloidosis, hereditary renal, 105200 (1)	4q28
Abetalipoproteinemia (1)	2p24	Amyloidosis, Iowa type, 107680.0010 (1)	11q23
[Acanthocytosis, one form] (1)	17q21-q22	[Amyloidosis, secondary, susceptibility to] (1)	11q21-q23
Acatalasemia (1)	11p13	Amyloidosis, senile systemic (1)	18q11.2-q12.1
Acetyl-CoA carboxylase deficiency (1)	17q21	Amyotrophic lateral sclerosis, juvenile (2)	2q35-q36
Acid-maltase deficiency, adult (1)	17q23	Amyotrophic lateral sclerosis, one form, 105400 (3)	2/q22.1
Acoustic neuroma (2)	22q12.2	Anal canal carcinoma (2)	11q22-qter
Acrocallosal syndrome (2)	13p13.3-p11.2	Analbuminemia (1)	4q11-q13
ACTH deficiency (1)	2p25	Anemia, megaloblastic, due to DHFR deficiency (1)	8q11.2-q13.2
Acyl-CoA dehydrogenase, long chain, deficiency of (1)	2q34-q35	Anemia, pernicious, congenital, due to deficiency of intrinsic factor (1)	Chr.11
Acyl-CoA dehydrogenase, medium chain, deficiency of (1)	1p31	Anemia, sideroblastic/hypochromic (3)	Xq18
Acyl-CoA dehydrogenase, short chain, deficiency of (1)	12q23-qter	Aneurysm, familial, 100070 (1)	Xp11.21
Adenylosuccinase deficiency (1)	22q13.1	Angelman syndrome (2)	2q31
Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency (1)	8q21	Angiodema, hereditary (1)	15q11-q13
Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency (3)	6p21.3	Anhidrotic ectodermal dysplasia (2)	11q11-q13.1
Adrenal hyperplasia V (1)	10q26.3	Aniridia of WAGR syndrome (2)	Xq12.2-13.1
Adrenal hypoplasia, primary (2)	Xp21.3-p21.2	Aniridia-2 (3)	11p13
Adrenocortical carcinoma (2)	11p15.5	Aniridia-3 (3)	11p13
Adrenocortical carcinoma, hereditary (2)	11p15.5	Ankylosing spondylitis (2)	6p21.3
Adrenoleukodystrophy (2)	Xq28	Anophthalmos-1 (2)	Xq27-q28
Adrenomyeloneuropathy (2)	Xq28	Anterior segment mesenchymal dysgenesis (2)	4q28-q31
[AFP deficiency, congenital] (1)	4q11-q13	Antithrombin III deficiency (3)	1q23-q25
Agammaglobulinemia, type 1, X-linked (3)	Xq21.3-q22	ApoA-I and apoC-III deficiency, combined (1)	11q23
Agammaglobulinemia, type 2, X-linked (2)	Xq22	Apolipoprotein B-100, defective (1)	2p34
Aicardi syndrome (2)	Xp22	[Apolipoprotein H deficiency] (1)	17q23-qter
Alagille syndrome (2)	20p11.2	Argininemia (1)	6q23
Albinism (3)	11q14-q21	Argininosuccinicaciduria (1)	7cen-q11.2
Albinism, brown, 203280 (1)	9p33	Aspartylglucosaminuria (3)	4q23-q27
Albinism, oculocutaneous, type II (3)	15q11.3-q12	Ataxia-cerebellar ataxia (2)	11q22-q23
Albinism-deafness syndrome (2)	Xq26.3-q27.1	[Atherosclerosis, susceptibility to] (2)	19p13.3-p13.2
[Albright hereditary osteodystrophy-3] (3)	15q11-q13	[Atherosclerosis, susceptibility to] (3)	8p21-p12
Alcohol intolerance, acute (1)	12q24.2	Atopy (2)	11q12-q13
[Aldolase A deficiency] (1)	16q22-q24	Attransferrinemia (1)	3q21
Allosteric, glucocorticoid-remediable (1)	8q31	Atrial septal defect, secundum type (2)	6p21.3
Allan-Herndon syndrome (2)	Xq21	Autonomic failure due to DBH deficiency (1)	9q34
Alpha-1-antichymotrypsin deficiency (1)	14q32.1	Basal cell nevus syndrome (2)	9q31
Alpha-NAGA deficiency (1)	22q11	Batten disease (2)	16p12
Alpha-thalassemia/mental retardation syndrome, type I (1)	16pter-p13.3	[Batten disease, one form, 204200 (1)]	15q24-q25
Alpha-thalassemia/mental retardation syndrome, type 2 (2)	Xq12-q21.31	Becker muscular dystrophy (3)	Xp21.2
Alport syndrome, 301050 (3)	Xq22	Reckwith-Wiedemann syndrome (2)	11pter-p16.4
Alveolar proteinosis, congenital, 265120 (1)	Chr.2	Bernard-Soulier syndrome (1)	17pter-p12
Alzheimer disease, APP related (3)	21q21.3-q22.05	Blepharophimosis, epicanthus inversus and ptosis (2)	3q22-q23
[Alzheimer disease-1] (2)	21q	Bloom syndrome (2)	16q26.1
Alzheimer disease-2 (2)	14q24.3	Borjeson-Forsman-Lehmann syndrome (2)	Xq26-q27
Alzheimer disease-3 (2)	19cen-q13.2	Bornholm eye disease (2)	Xq28
Amelogenesis imperfecta (1)	Xp22.3-p22.1	Branchiootic syndrome (2)	8q13.3
[Amelogenesis imperfecta-3, hypoplastic type] (2)	Xq22-q23	[Breast cancer] (1)	17p13.3
		Breast cancer (1)	6q24-q27
		Breast cancer, ductal (2)	1p36
		Breast cancer, ductal (2)	Chr.13
		Breast cancer-L, early onset (2)	17q21

Disorder	Location	Disorder	Location
Brady myopathy (1)	Chr16	Colorblindness, tritan (2)	7q22-qter
Burkitt lymphoma (3)	8q24.12-q24.13	Colorectal adenoma (1)	12p12.1
C1q deficiency (1)	1p36.3-p34.1	Colorectal cancer (1)	12p12.1
C1r/C1s deficiency, combined (1)	12p13	Colorectal cancer (1)	18q23.3
C2 deficiency (3)	6p21.3	Colorectal cancer (1)	8q21
C3 deficiency (1)	18p13.3-p13.1	Colorectal cancer, 114500 (3)	17p13.1
C3b inactivator deficiency (1)	4q25	Colorectal cancer (3)	5p21-q22
C4 deficiency (3)	6p21.3	Combined C5/C7 deficiency (1)	6p13
C5 deficiency (1)	8q34.1	*Combined variable hypogammaglobulinemia (1)	14q32.33
C6 deficiency (1)	5p13	Congenital bilateral absence of vas deferens (1)	7q31.3
C7 deficiency (1)	5p13	*Congenital cardiac anomalies (2)	22q11
C8 deficiency, type I (2)	1p32	Contractural arachnodactyly, congenital (3)	Chr.5
C8 deficiency, type II (2)	1p32	Coproporphria (1)	Chr.9
C9 deficiency (1)	5p13	*Corbetta de Lange syndrome (2)	3q28.3
Campanelle dysplasia-1 (2)	17q34.3-q25.1	(Coronary artery disease, susceptibility to) (1)	6q27
Carbamoylphosphate synthetase I deficiency (1)	2p	Cortisol resistance (1)	5q31
*Carbonic anhydrase I deficiency (1)	8q22	CR1 deficiency (1)	10q2
Carboxypeptidase B deficiency (1)	Chr.18	*Craniobrownschmal dysplasia (2)	Xp22-q22.3
*Cardiomyopathy (1)	2q35	Craniocystoma, type II (2)	8q34-qter
Cardiomyopathy, dilated, X-linked (1)	Xp21.2	Craniosynostosis, type I (2)	7p21.3-p21.2
Cardiomyopathy, familial hypertrophic, 1, 192800 (3)	14q12	Crestline disease, brain type, ectopic expression of (2)	14q32
Cardiomyopathy, familial hypertrophic, 2 (2)	1q5	Cretzfeldt-Jakob disease, 123400 (3)	2pter-q12
Cardiomyopathy, familial hypertrophic, 3 (2)	15q2	Criple-Nager syndrome, type I, 218300 (1)	Chr.2
Cardiomegaly, hypoplasia (2)	9p13-q11	*Cryptorchidism (2)	Xp21
Cas-eye syndrome (2)	22q11	*Crisis laxa, marfanoid neonatal type (1)	7q31.1-q31.3
*Cataract, anterior polar, 1 (2)	14q24-qter	(Cystathionuria) (1)	Chr.16
*Cataract, congenital total (2)	3p	Cystic fibrosis (2)	7q31.2
Cataract, congenital, with microphthalmia (2)	18p12.3	*Cystinuria (2)	14q22
Cataract, Coppock-like (3)	2q33-q35	*Cystinuria, 220100 (1)	2pter-q22.3
Cataract, Marfan type (2)	16q22.1	Deafness, conductive, with stapes fixation (2)	Xq13-q21.1
Cataract, senile pulverulent-1 (2)	1q2	Deafness, low-tone (2)	5q31-q33
CD3 zeta chain, deficiency (1)	1q25-q27.1	Debrunquus arachnoid (1)	22q12.1
Cerebral core disease (2)	14q12	Destinogenesis imperfecta-1 (2)	4q13-q21
Cerebral core disease of muscle (2)	17p13.1	Dennis-Draugh syndrome (1)	11p13
Cervicofacial lymphoma (2)	11q13	Diabetes insipidus, nephrogenic (2)	Xq28
Cerebral amyloid angiopathy (1)	20p11	Diabetes insipidus, neurohypophyseal, 125700 (1)	20p13
Cerebral arteriovenous malformation and leucodystrophy (2)	18q12	*Diabetes mellitus, insulin-dependent-1 (2)	6p21.3
Cerebromeningeal xanthomatosis (2)	2q33-qter	Diabetes mellitus, insulin-resistant, with acanthosis nigricans (1)	19p12.2
Cereoid lipofuscinosis, neuronal-1, infantile (2)	1p32	Diabetes mellitus, rare form (1)	11p15.5
Cervical carcinoma (2)	11q13	Dysastrophic dysplasia (2)	5q31-q34
(CETP deficiency) (1)	16q21	DiGeorge syndrome (2)	22q11
Charcot-Marie-Tooth neuropathy, slow nerve conduction type Ia (2)	17p11.2	Diphenylhydantoin toxicity (1)	1p11-qter
Charcot-Marie-Tooth neuropathy, slow nerve conduction type Ib (2)	1q21.3-q23	(Diphtheria, susceptibility to) (1)	5q23
Charcot-Marie-Tooth neuropathy, X-linked-1, dominant (2)	Xq13	DNA ligase I deficiency (1)	18q13.2-q18.3
Charcot-Marie-Tooth neuropathy, X-linked-2, recessive (2)	Xp22.2	*Dolan-Johnson syndrome (2)	13q34
Cholesteryl ester storage disease (1)	10q24-q25	Duchenne muscular dystrophy (3)	Xp21.2
*Chondrodysplasia punctata, rhizomelic (2)	4p16-p14	(Dysalbuminemic hyperthrombocytosis) (1)	4q11-q13
Chondrodysplasia punctata, X-linked dominant (2)	Xq28	(Dysalbuminemic hyperthrombocytosis) (1)	4q11-q13
Chondrodysplasia punctata, X-linked recessive (2)	Xp22.3	Dysalbuminemia, familial (2)	9q31-q33
Choroideremia (2)	Xq21.2	Dysalbuminemia, alpha types (1)	4q28
Chronic granulomatous disease, autosomal, due to deficiency of CYBA (3)	16q34	Dysalbuminemia, beta types (1)	4q28
Chronic granulomatous disease due to deficiency of NCF-1 (1)	7q11.23	Dysalbuminemia, gamma types (1)	4q28
Chronic granulomatous disease due to deficiency of NCF-2 (1)	1q25	Dyskeratosis congenita (2)	Xq28
Chronic granulomatous disease, X-linked (3)	Xp21.1	*Dyskeratosis-1 (2)	15q11
(Chronic infections, due to upsonin defect) (1)	10q11.2-q21	Dysphagminergic thrombophilia (1)	6q28-q27
Cirrhosis (1)	9q34	Dysprothrombinemia (1)	11p11-q12
Cleft palate, X-linked (2)	Xq13-q21.31	(Dysprothrombinemic hyperthrombocytosis) (1)	18q11.2-q12.1
*Cleidocranial dysplasia (2)	8q22	*ECC syndrome (2)	7q11.2-q21.3
CMO II deficiency (1)	8q21	Ehlers-Danlos syndrome, type IV, 130060 (3)	2q31
Cockayne syndrome-2, late onset, 216410 (2)	10q11	Ehlers-Danlos syndrome, type VI, 225400 (1)	16p36.3-p36.2
Coffin-Lowry syndrome (2)	10p22.2-p22.1	Ehlers-Danlos syndrome, type VIIA1, 130060 (3)	17q21.31-q22.05
Colon cancer, familial, nonpolyposis type 1 (2)	2p18-p16	Ehlers-Danlos syndrome, type VIIA2, 130060 (3)	7q22.1
Colorblindness, blue monochromatic (3)	Xq28	*Ehlers-Danlos syndrome, type X (1)	2q34
Colorblindness, deutan (3)	Xq28	(Elliptocytosis, Malaysian-Malaysian type) (1)	17q21-q22
Colorblindness, protan (3)	Xq28	Elliptocytosis-1 (3)	16p36.3-p34
		Elliptocytosis-2 (2)	1q21
		Elliptocytosis-3 (2)	14q22-q23.2
		Emery-Dreifuss muscular dystrophy (2)	Xq28
		Emphysema (1)	14q32.1
		Emphysema due to alpha-1-antitrypsin deficiency (1)	12p13.3-p12.3

Disorder	Location	Disorder	Location
Empyema-cirrhosis (1)	14q32.1	Glaucoma, congenital (2)	Chr.11
Endocardial fibroelastosis-2 (2)	Xq38	Glaucoma, primary open angle (2)	1q21-q31
Enolase deficiency (1)	1pter-p36.13	Glioblastoma multiforme (2)	10p12-q23.2
?Eosinophilic myeloproliferative disorder (2)	12p13	Glucose/galactose malabsorption (1)	22q11.2-qter
Epidermolysis bullosa dystrophica, dominant, 131750 (3)	3p21.3	Gluconicidemia type IIC (8)	4q33-qter
Epidermolysis bullosa dystrophica, recessive, 226600 (3)	3p21.3	Gluconicidemia, type IIA (1)	15q25-q25
Epidermolysis bullosa, Ogna type (3)	8q24	Gluconicidemia, type IIB (8)	Chr.19
Epidermolysis bullosa simplex, 131900 (3)	17q12-q21	Glutathionuria (1)	22q11.1-q11.2
Epidermolysis bullosa simplex, Dowling-Meara type, 181700 (3)	13q11-q13	Glycerol kinase deficiency (2)	Xp21.3-p21.2
Epidermolysis bullosa simplex, Dowling-Meara type, 131700 (3)	17q12-q21	Glycogen storage disease III (8)	1p21
Epidermolysis bullosa simplex, generalized, 131800 (1)	12q11-q13	Glycogen storage disease VII (1)	1cen-q32
?Epidermolysis bullosa simplex, localized, 131800 (1)	12q11-q13	Glycogen storage disease, X-linked hepatic (2)	Xp22.2-p32.1
?Epidermolysis bullosa, Weber Cockayne type, 131800 (2)	12q11-q13	[Glyoxalase II deficiency] (1)	16p13
Epidermolysis hyperkeratosis, 118800 (1)	17q31-q32	GM1-gangliosidosis (1)	3p21-p14.2
Epidermolysis hyperkeratosis, 118800 (8)	12q11-q13	GM2-gangliosidosis, AB variant (1)	Chr.5
Epidermolysis palmoplantar keratoderma (2)	17q11-q23	GM2-gangliosidosis, juvenile, adult (1)	15q23-q24
Epidermolysis palmoplantar keratoderma (2)	20q13.3-q13.3	Goemann TACR syndrome (2)	Xq28
Epidermolysis palmoplantar keratoderma (2)	6p21.3	Gorlin, adolescent, multinodular (1)	8q24.2-q24.3
Epidermolysis palmoplantar keratoderma (2)	21q22.3	Gorlin, neonatal, simple (1)	8q24.2-q24.3
Epidermolysis palmoplantar keratoderma (2)	9q31	?Goldenhar syndrome (2)	7p
Epidermolysis palmoplantar keratoderma (2)	7q21	Gonadal dysgenesis, XY female type (2)	Xp22-p21
Epidermolysis palmoplantar keratoderma (2)	16pter-p13.3	Gonadal dysgenesis, XY type (1)	Yp11.3
Epidermolysis palmoplantar keratoderma (2)	11p15.5	Gonadoblastoma (2)	11p13
Epidermolysis palmoplantar keratoderma (2)	1p36.3-p34	?Gonadotropin deficiency (2)	Xq21
Epidermolysis palmoplantar keratoderma (2)	19p13.3-p13.3	Orvig craniofaciosyndactyl syndrome (3)	7p13
Epidermolysis palmoplantar keratoderma (2)	1p36.3-p34	?Oryzomastix, familial, due to increased	
Epidermolysis palmoplantar keratoderma (2)	22q12	aromatase activity (1)	16q21.1
Epidermolysis palmoplantar keratoderma (2)	22q12	Oocyte atrophy of choroid and retina with ophthalmia,	
Epidermolysis palmoplantar keratoderma (2)	11p15.4	B6 responsive or unresponsive (1)	10q26
Epidermolysis palmoplantar keratoderma (2)	Xq21.31	Harderoporphyria (1)	Chr.9
Epidermolysis palmoplantar keratoderma (2)	Xq22	?Hematuria disease, 254800 (1)	2pter-q23.3
Epidermolysis palmoplantar keratoderma (2)	4q35	Heinz body anemia, alpha- (1)	16pter-q13.3
Epidermolysis palmoplantar keratoderma (2)	1q32	Heinz body anemia, beta- (1)	11p15.5
Epidermolysis palmoplantar keratoderma (2)	1q23	Hemochromatosis (2)	6p21.3
Epidermolysis palmoplantar keratoderma (2)	13q34	Hemodialysis-related amyloidosis (1)	15q21-q22
Epidermolysis palmoplantar keratoderma (2)	13q34	Hemolytic anemia due to ALA excess (1)	20q13.1
Epidermolysis palmoplantar keratoderma (2)	4q35	Hemolytic anemia due to adenylate kinase deficiency (1)	9q34.1
Epidermolysis palmoplantar keratoderma (2)	5q33-qter	Hemolytic anemia due to bisphosphoglycerate mutase	
Epidermolysis palmoplantar keratoderma (2)	6p23-p24	deficiency (1)	7q31-q34
Epidermolysis palmoplantar keratoderma (2)	1q31-q32.1	Hemolytic anemia due to G6PD deficiency (1)	Xq23
Epidermolysis palmoplantar keratoderma (2)	16p13	Hemolytic anemia due to glucose-6-phosphate isomerase	
Epidermolysis palmoplantar keratoderma (2)	1q42	deficiency (1)	19q13.1
Epidermolysis palmoplantar keratoderma (2)	20q13.3-q13.3	Hemolytic anemia due to glutathione peroxidase	
Epidermolysis palmoplantar keratoderma (2)	Xq28	deficiency (1)	3q11-q12
Epidermolysis palmoplantar keratoderma (2)	10q24.2	Hemolytic anemia due to glutathione reductase	
Epidermolysis palmoplantar keratoderma (2)	1p11-qter	deficiency (1)	8p21.1
Epidermolysis palmoplantar keratoderma (2)	20p12	Hemolytic anemia due to hexokinase deficiency (1)	10q32
Epidermolysis palmoplantar keratoderma (2)	16q22.1	Hemolytic anemia due to PKG deficiency (1)	Xq13
Epidermolysis palmoplantar keratoderma (2)	1q	Hemolytic anemia due to phosphatidylase deficiency (1)	21q22.3
Epidermolysis palmoplantar keratoderma (2)	4q35	Hemolytic anemia due to uricase deficiency (1)	12p13
Epidermolysis palmoplantar keratoderma (2)	Xq22.31	Hemophilia A (3)	Xq28
Epidermolysis palmoplantar keratoderma (2)	9q13-q21.1	Hemophilia B (3)	Xq27.1-q27.2
Epidermolysis palmoplantar keratoderma (2)	9q32	Hemorrhagic diathesis due to "antithrombin" Pittsburgh (1)	14q32.1
Epidermolysis palmoplantar keratoderma (2)	1p34	Hemorrhagic diathesis due to PAI deficiency (1)	7q21.3-q22
Epidermolysis palmoplantar keratoderma (2)	14q2.1	?Hepatic lipase deficiency (1)	15q21-q23
Epidermolysis palmoplantar keratoderma (2)	Xq23	?Hepatocarcinoma (1)	2q14-q21
Epidermolysis palmoplantar keratoderma (2)	17q21-q22	Hepatocellular carcinoma (3)	4q32.1
Epidermolysis palmoplantar keratoderma (2)	1p36-p35	[Hereditary persistence of alpha-fetoprotein] (3)	4q11-q13
Epidermolysis palmoplantar keratoderma (2)	9p13	?Hereditary persistence of fetal hemoglobin (3)	11p15.5
Epidermolysis palmoplantar keratoderma (2)	20q13.1	?Hereditary persistence of fetal hemoglobin,	
Epidermolysis palmoplantar keratoderma (2)	5q31-q32	heterocellular, Indian type (2)	7q36
Epidermolysis palmoplantar keratoderma (2)	10q21-q22	?Hereditary persistence of fetal hemoglobin, Swiss type (2)	Xp11.23
Epidermolysis palmoplantar keratoderma (2)	11p13	?Hermansky-Pudlak syndrome, 203800 (1)	18q16
Epidermolysis palmoplantar keratoderma (2)	20pter-p12	Hers disease, or glycogen storage disease VI (1)	Chr.14
Epidermolysis palmoplantar keratoderma (2)	Chr.2	Heterozygous hereditary persistence of fetal hemoglobin (2)	11p15
Epidermolysis palmoplantar keratoderma (2)	17q21.32	[Hex A pseudodeficiency] (1)	15q23-q24
Epidermolysis palmoplantar keratoderma (2)	17q21.32	?HHN syndrome (2)	13q34
Epidermolysis palmoplantar keratoderma (2)		[Himidineuria] (1)	12q22-q23
Epidermolysis palmoplantar keratoderma (2)		Holoprosencephaly, type 3 (2)	7q36
Epidermolysis palmoplantar keratoderma (2)		?Holt-Orlitzky syndrome (2)	18pter-q11

<i>Disorder</i>	<i>Location</i>	<i>Disorder</i>	<i>Location</i>
?Holoencephaly-3 (3)	2p31	absent GH and Kowarski type with bioinactive GH (3)	17q22-q24
?Holoencephaly-4 (3)	16q11.1-q18	Isovaleric acidemia (1)	15q14-q15
?Holt-Orwin syndrome (2)	16q23-q34.2	Jacobson syndrome (3)	11q
?Holt-Orwin syndrome (3)	20p13		
Homozygous B <sub>6</sub> -responsive and nonresponsive types (1)	21q22.3		
HPPH, deletion type (1)	11p15.5	Kallmann syndrome (2)	Xp22.3
HPPH, nondelation type A (1)	11p15.5	[Kappa light chain deficiency] (1)	2p12
HPPH, nondelation type G (1)	11p15.5	Keratin follicular spinulosa decalvans (2)	Xp22.3-p21.2
HPT-related gout (1)	Xq26-q27.2	[Kininen deficiency] (1)	3q26-qter
?Humoral hypercalcemia of malignancy (1)	12p12.1-p11.2	Klippel-Trépan syndrome (3)	5q11.3
Huntington disease (2)	4p16.3	Kniest dysplasia (1)	12q13.11-q13.2
Hurler syndrome (1)	4p16.3	?Kostmann aggranulocytosis (2)	6p21.3
Hurler-Scheie syndrome (1)	4p16.3	Krabbe disease (1)	14q24.3-q32.1
Hydranphalus due to aqueduct of Sylvius, 207000 (3)	Xq23	Lactase deficiency, adult, 223100 (1)	Chr.2
Hydrops fetalis, one form (1)	19q13.1	Lactase deficiency, congenital (1)	Chr.2
Hyperammonemia due to CTPost deficiency (1)	11p13-p11	Lactoferrin-deficient neutrophils, 245400 (1)	3q21-q23
Hyperbetalipoproteinemia (1)	2p24	Langer-Giedion syndrome (2)	3q24.11-q24.13
Hyperkalemia, hypokalemic, familial (3)	2q31-q34	Langer-Saldino achondrognath-hypochondrogenesis (1)	12q13.11-q13.2
Hypercholesterolemia, familial (3)	19p13.2-p13.1	Larva ovariata (1)	5p13-p12
?Hyperglycemia, isolated nonketotic, type I (2)	8p22	?Laryngeal adductor paralysis (2)	6p21.3-p21.2
?Hyperimmunoglobulin G1 syndrome (2)	14q32.33	[Lead poisoning, susceptibility to] (1)	9q34
Hyperkalemic periodic paralysis (3)	17q21.1-q25.3	?Leontiasis, multiple hereditary cutaneous (2)	18p11.32
?Hyperleucinemia-isoleucineuria or hypervalinemia (1)	12pter-q12	Lesch-Nyhan syndrome (3)	Xo22
Hyperlipoproteinemia I (1)	6p22	Leptochloasma (1)	19p19.2
Hyperlipoproteinemia, type II (1)	19p13.2	Letech-Nyhan syndrome (3)	Xo22-q27.2
Hyperlipoproteinemia, type III (1)	19q13.2	?Letover-severe disease (2)	13q14-q31
[Hyperphenylalaninemia, mild] (3)	12q24.1	Leukemia, acute lymphoblastic (1)	19p13.3
[?Hyperproliferation] (1)	2q38-q37	Leukemia, acute lymphoblastic (2)	9p23-p31
Hyperproteinemia, familial (1)	11p15.5	?Leukemia, acute lymphocytic, with 4/11 translocation (3)	4q21
Hyperuricemia, essential, 145500 (1)	17q21-q23	Leukemia, acute myeloid (3)	21q22.3
[Hyperuricemia, essential, susceptibility to] (3)	1q43-q43	Leukemia, acute myeloid, M2 type (1)	Xp22.32
Hypertriglyceridemia, one form (1)	11q23	Leukemia, acute pro-B-cell (2)	1q23
?Hyperuricemia or hyperleucine-isoleucineuria (1)	Chr.19	Leukemia, acute promyelocytic (1)	17q21.1
Hypoalbuminemia (1)	11q23	Leukemia, acute promyelocytic (2)	15q22
Hypobetalipoproteinemia (1)	2p24	Leukemia, acute, T-cell (2)	11p13
Hypocalcaemic hyperparathyroidism, type II (2)	19p13.3	Leukemia, chronic myeloid (3)	22q11.21
[Hypoceruloplasminemia, hereditary] (1)	3q21-q24	Leukemia, chronic myeloid (3)	9q34.1
Hypofibrinogenemia, gamma types (1)	4q28	Leukemia, undifferentiated (2)	Chr.4
?Hypoglycemia due to PCK1 deficiency (1)	20q13.31	Leukemia, myeloid/lymphoid or mixed-lineage (2)	11q23
Hypomagnesemia, hypergonadotropic (1)	19q13.32	Leukemia, T-cell acute lymphoblastic (2)	11p15
?Hypomagnesemia, hypogonadotropic due to OHRH deficiency, 227200 (1)	8p21-p11.2	Leukemia, T-cell acute lymphoblastic (2)	9q34.3
Hypomagnesemia, X-linked primary (2)	Xp22	Leukemia, T-cell acute lymphoblastic (2)	19p13.3-p13.1
?Hypomelanosis of Ito (2)	15q11-q13	Leukemia, T-cell acute lymphocytic (2)	10q24
?Hypomelanosis of Ito (2)	9q33-qter	?Leukemia, transverse (2)	21q11.2
Hypoparathyroidism, familial (1)	11p15.3-p15.1	Leukemia-1, T-cell acute lymphoblastic (3)	11p13
Hypoparathyroidism, X-linked (2)	Xq26-q27	Leukemia-2, T-cell acute lymphoblastic (3)	9q31
?Hypophosphatemia, adult, 148300 (1)	1p36.1-p34	Leukemia/lymphoma, B-cell, 1 (2)	11q13
Hypophosphatemia, infantile, 241500 (3)	1p36.1-p34	Leukemia/lymphoma, B-cell, 2 (2)	18q21.3
Hypophosphatemia, hereditary (2)	Xp22.2-q22.1	Leukemia/lymphoma, B-cell, 3 (2)	19q13
?Hypophosphatemia with deafness (2)	Xp22	Leukemia/lymphoma, T-cell (2)	14q32.1
Hypoprothrombinemia (1)	11p11-q12	Leukemia/lymphoma, T-cell (2)	2q34
?Hypopygia-dysphagia syndrome (2)	5p13-p12	Leukemia/lymphoma, T-cell (3)	14q11.2
Hypothyroidism, hereditary congenital (1)	8q24.3-q24.8	Leukocyte adhesion deficiency (1)	21q22.3
Hypothyroidism, nongestational (1)	1p13	Li-Fraumeni syndrome (1)	17p13.1
Hypothyroidism, nongestational, due to TSH resistance (1)	14q31	Lipamide dehydrogenase deficiency (1)	7q31-q32
Ichthyosis vulgaris, 145700 (1)	1q21	Luoma (2)	12q13-q14
Ichthyosis, X-linked (3)	Xp22.32	Liver cell carcinoma (1)	11p14-p13
Immunodeficiency, X-linked (3)	8p	Long QT syndrome (2)	11p15.5
Incontinentia pigmenti, familial (2)	Xq24-q27	Love syndrome (3)	Xq28.1
Incontinentia pigmenti, sporadic type (2)	Xq27-q28	Lupus erythematosus, systemic, 152700 (1)	1q23
Infertile male syndrome (1)	Xp11.21	Lymphoproliferative syndrome, X-linked (2)	Xq25
[Inosine triphosphatase deficiency] (1)	Xcen-q22	?Lynch cancer family syndrome II (2)	18q11-q12
Insomnia, fatal familial (3)	20p	?Lysosomal acid phosphatase deficiency (1)	11p12-p11
Intestinal-dependent diabetes mellitus-3 (2)	20pter-p12	Macrocytic anemia of Sq-syndrome, refractory (2)	3q12-q32
Interferon, alpha, deficiency (1)	11q		
Interferon, gamma, deficiency (1)	9p21		
?Isolated growth hormone deficiency due to defect in GHRF (1)	22q24.1		
Isolated growth hormone deficiency, III type var.	20p11.23-qter		

Disorder	Location	Disorder	Location
?Male infertility due to acrosin deficiency (2)	22q13-qter	Multiple endocrine neoplasia II (2)	10q11.2
?Male infertility, familial (1)	11p13	Multiple endocrine neoplasia III (2)	10q11.2
?Male pseudohermaphroditism due to defective LH (1)	18q13.32	?Multiple osteomas (2)	8q23-q24.1
Malignant hyperthermia susceptibility-1, 145800 (2)	18q13.1	?Multiple lipomatosis (2)	12q13-q14
Malignant hyperthermia susceptibility-2, 145800 (2)	17q21.31-q24	(Multiple osteomas, susceptibility to) (2)	18q23-qter
Malignant melanoma, cutaneous (2)	1p36	?Muscle glycogenosis (1)	Xq12-q13
?Manic-depressive illness, X-linked (2)	Xq28	Muscular dystrophy, Duchenne-like, autosomal (2)	18q13-q18
Marfanoidism (1)	19p13.2-q12	Muscular dystrophy, limb-girdle, autosomal	
Maple syrup urine disease, type 1 (3)	19q13.1-q12.2	downs (2)	5q22.3-q31.3
Maple syrup urine disease, type 2 (2)	1p31	Muscular dystrophy, limb-girdle, autosomal recessive (2)	16q15-q22
Maple syrup urine disease, type 3 (1)	8p22-p21	Myoblastic dysplasia, proteoblastic (2)	8q21.1
Martin syndrome, 154700 (3)	15q21.1	Myelogenous leukemia, acute (3)	5q31.1
Maroteaux-Lamy syndrome, several forms (1)	5q11-q13	Myeloperoxidase deficiency (1)	17q21.3-q22
Martin-Bell syndrome (2)	Xq27.3	Myosin heavy chain deficiency (1)	1p21-p13
MASA syndrome (2)	Xq28	(Myocardial infarction, susceptibility to) (3)	17q28
McArdle disease (1)	11q13	Myoglobinuria/hemolysis due to PGK deficiency (1)	Xq13
McCune-Albright polyostotic fibrous dysplasia, 174800 (1)	20q13.2	Myopathy due to CTPase deficiency (1)	1p13-p11
McLeod phenotype (2)	Xp21.2-p21.1	Myopathy due to phosphoglycerate mutase deficiency (1)	7p13-p12.3
Medullary thyroid carcinoma (2)	10q11.2	Myopia-1 (2)	Xq28
Megacolon (2)	10q11.2	Myotonia congenita, typical acetazolamide-responsive (2)	17q23.1-q25.3
Megalocornea, X-linked (2)	Xq11.3-q22	Myotonia congenita, dominant, 160800 (2)	7q35
Melanoma, cutaneous malignant (2)	9p21	Myotonia congenita, recessive, 255700 (3)	7q35
Meningioma (2)	22q12.3-qter	Myotonic dystrophy (2)	19q13.2-q13.3
Meningioma (3)	22q12.3-q13.1	Myotubular myopathy, X-linked (2)	Xq28
Merkel disease (2)	Xq12-q13	Myxoid liposarcoma (2)	12q13-q14
Mental retardation of WAGR (2)	11p13	N	
Mental retardation, Snyder-Robinson type (2)	Xp21	?N syndrome, 310455 (1)	Xp22.3-p21.1
?Mental retardation, X-linked nonspecific, with aphasia (2)	Xp11	Nail-patella syndrome (2)	9q34
Mental retardation, X-linked, syndromic-1, with dystonic movements, ataxia, and seizures (2)	Xp22.3-q22.1	Nance-Horan syndrome (2)	Xp22.3-p21.1
Mental retardation, X-linked, syndromic-2, with dysmorphism and cerebral atrophy (2)	Xp11-q21	Nemaline myopathy-1 (2)	1q21-q23
Mental retardation, X-linked, syndromic-3, with spastic diplegia (2)	Xp11-q21.3	Nephrosesphathia, juvenile (2)	2p13-q14
Mental retardation, X-linked, syndromic-4, with congenital contractures and low finger arches (2)	Xq18-q22	Neuroblastoma (2)	1p36.3-p38.1
Mental retardation, X-linked, syndromic-5, with Dandy-Walker malformation, basal ganglia disease, and seizures (2)	Xq28-q27	Neuroepithelioma, 133455 (1)	11q23-q34
Mental retardation, X-linked, syndromic-6, with gyromatosis and obesity (2)	Xp21.1-q22	Neurofibromatosis (2)	22q12
Mental retardation, X-linked-1, non-dysmorphic (2)	Xp22	Neurofibromatosis, von Recklinghausen (3)	17q11.2
?Mental retardation, X-linked-2, non-dysmorphic (2)	Xq11-q12	Neuropathy, recurrent, with pressure palsies, 163400 (3)	17p11.3
Mental retardation, X-linked-3 (2)	Xq28	Neutropenia, immune (2)	10q23
Mental retardation-skeletal dysplasia (2)	Xq28	Niemann-Pick disease, type A (1)	11p15.4-15.1
Metachromatic leukodystrophy (1)	22q13.31-qter	Niemann-Pick disease, type B (1)	11p15.4-15.1
Metastatic leukodystrophy due to deficiency of SAP-1 (1)	10q21-q22	Niemann-Pick disease, type C (3)	18p
Metmetoglobinemia due to cytochrome b5 deficiency (2)	Chr.14	Nightblindness, congenital stationary, type 1 (2)	Xp11.3
Metmetoglobinemia, enzymopathic (1)	22q13.31-qter	?Non-insulin dependent diabetes mellitus, susceptibility to (2)	19q13.3
Metmetoglobinemia, alpha- (1)	10pter-p13.3	Nerve disease (2)	Xp11.4
Metmetoglobinemia, beta- (1)	11p15.5	Nervous disease (3)	16q22.1
Methylmalonicaciduria, mutase deficiency type (1)	8p21	Nucleoside phosphorylase deficiency, immunodeficiency due to (1)	14q12.1
Mucopolysaccharidosis I (1)	Chr.12	?Obesity (2)	7q31
?Microphthalmia with linear skin defects (2)	Xp22.2	?Ocular albinism autosomal recessive (2)	6q12-q15
Miller-Dieker lissencephaly syndrome (2)	17p13.3	Ocular albinism, Forster-Eriksson type (2)	Xp11-q11
?Mitochondrial complex I deficiency, 252010 (1)	11q18	Ocular albinism, Nettleship-Falls type (2)	Xp22.3
MODY, one form (3)	11p15.5	Ornithine transcarbamylase deficiency (3)	Xp21.1
MODY, type 1 (2)	20q13	Oral cleft (2)	6pter-q23
MODY, type 2, 125851 (3)	7p16-p13	Oroticaciduria (1)	3q13
?Morbus syndrome (2)	13q12.3-q13	Osteoarthritis, precocious (3)	12q13.11-q13.2
?Mucopolysaccharidosis I (1)	16q13-q22.1	Osteoarthritis, imperfect, a clinical form, 166200, 166210, 259420, 166220 (3)	17q21.31-q22.05
Mucopolysaccharidosis II (2)	4q21-q23	Osteoarthritis, imperfect, a clinical form, 166200, 166210, 259420, 166220 (3)	7q22.1
Mucopolysaccharidosis III (1)	4p16.3	?Osteopetrosis, 259700 (1)	1p21-p13
Mucopolysaccharidosis IV (3)	Xq28	Osteopetrosis, idiopathic, 164710 (3)	17q21.31-q22.05
Mucopolysaccharidosis V (1)	18q24.3	Osteosarcoma, 258500 (2)	13q14.1-q14.2
Mucopolysaccharidosis VI (1)	3p21-p14.2	Uteral leiomyoma syndrome, type 1 (2)	Xq28
Mucopolysaccharidosis VII (1)	7q21.11	Ovarian carcinoma, 167000 (2)	19q13.1-q13.2
Multiple endocrine neoplasia I (1)	11q13	Ovarian carcinoma (2)	9p24
		Ovarian failure, premature (2)	Xq28-q27
		Oxalosis (1)	2q36-q37
		P	
		?Paget disease of bone (2)	6p21.3
		?Pallister-Hall syndrome (2)	3p21.3
		Pancreatic lipase deficiency (1)	10q26
		?Panhypopituitarism (1)	3q



Disorder	Location	Disorder	Location
?Panhypopituitarism, X-linked (2)	Xq21.3-q22	Retinitis pigmentosa, autosomal recessive (8)	3q21-q24
Paraganglioma (2)	11q22.3-q23.2	Retinitis pigmentosa, peripheral-related (8)	6p21.1-ene
Parasymptoma congenita, 16K50 (3)	17q21.1-q25.3	Retinitis pigmentosa-1 (2)	8p11-q21
Parathyroid adenomatosis (1)	11q13	Retinitis pigmentosa-2 (2)	Xp11.3
?Parietal foramina (2)	11p13-p11.12	Retinitis pigmentosa-3 (2)	Xp21.1
?Paroxysmal, susceptibility to (1)	22q13.1	Retinitis pigmentosa-4, autosomal dominant (8)	3q21-q24
Paroxysmal nocturnal hemoglobinuria (1)	Xq22.1	Retinitis pigmentosa-5 (2)	2q
Pelizaeus-Merzbacher disease (3)	Xq22	?Retinitis pigmentosa-6 (2)	Xp21.3-p21.2
Polyspermatid junction obstruction (2)	6p	Retinitis pigmentosa-8 (2)	7p16.1-p13
?Pendred syndrome (2)	8q24	Retinitis pigmentosa-10 (2)	7q
Periodontitis, juvenile (2)	4q11-q13	Retinitis punctata albescens (1)	6p21.1-ene
Persistent Müllerian duct syndrome (1)	19p13.3-p13.2	Retinoblastoma (3)	13q14.1-q14.2
Phenylketonuria (3)	12q24.1	?Retinol binding protein, deficiency of (1)	10q23-q24
Phenylketonuria due to dihydropteridine reductase deficiency (1)	4p15.31	Retinosischidia (2)	Xp22.3-p22.1
Phenothiazine (2)	1p	?Rett syndrome (2)	Xp
Phosphoribosyl pyrophosphate synthetase-related gout (1)	Xq23-q24	Rhabdomyosarcoma (2)	11p13.5
?Phosphorylase kinase deficiency of liver and muscle, 201750 (2)	16q12-q13.1	Rhabdomyosarcoma, alveolar (2)	2q37
Pituitary tumor, growth-hormone-secreting (1)	4q12	Rhabdomyosarcoma, alveolar (2)	2q35
PK deficiency hemolytic anemia (1)	20q13.2	Rh-null disease (1)	3cen-q22
?Placental lactogen deficiency (1)	1q21	?Rh-null hemolytic anemia (1)	1p36.3-p34
Placental steroid sulfatase deficiency (3)	17q23-q24	Nickle, vitamin D-resistant (1)	12q12-q14
Plasmin inhibitor deficiency (1)	Xp22.32	Anger syndrome (2)	4q25-q27
Plasminogen activator deficiency (1)	17pter-p12	Kod monochromasy (2)	Chr.14
Plasminogen deficiency, type I and II (1)	8p12	?Kohlschütter-Thompson syndrome (2)	Chr.14
Plasminogen Tochi disease (1)	6q26-q27	Rubinstein-Taybi syndrome (2)	16p13.3
Platelet alpha-thrombocyte storage pool deficiency (1)	6q26-q27	?Russell-Silver syndrome (2)	17q25
?Polar, susceptibility to (2)	10q23-q25	Saenger-Choctaw syndrome (2)	7p
Polycystic kidney disease (2)	16p13.3-q13.3	Salivary gland pleomorphic adenoma (2)	8q12
Polycystic ovarian disease (1)	16p13.31-p13.12	Sandhoff disease (1)	8q13
Polypoma coli, familial (3)	17q11-q12	Sandhoff disease, type III (2)	Chr.14
Pompe disease (1)	5q31-q32	Sandhoff syndrome D (1)	12q14
Porphyria, acute hepatic (1)	17q25	Sarcoma, synovial (2)	Xp11.2
Porphyria, acute intermittent (1)	8q24	Schaw syndrome (1)	4p16.3
Porphyria, Chester type (2)	11q24.1-q24.2	?Schizophrenia (2)	5q11.3-q13.3
Porphyria, congenital erythropoietic (1)	11q	Schizophrenia, chronic (2)	21q21.3-q22.06
Porphyria cutanea tarda (1)	10q25.3-q26.3	?Schizophrenia, susceptibility to (2)	2q18.3
Porphyria, hepatoerythropoietic (1)	1p34	Sclerostylosis (2)	4q28-q31
Porphyria variegata (2)	16q32	Severe combined immunodeficiency, 202300 (1)	10p16-p14
Postaxial polydactyly (1)	3q26.1-q26.2	Severe combined immunodeficiency due to ADA deficiency (1)	20q13.11
Prader-Willi syndrome (2)	15q11	Severe combined immunodeficiency due to IL2 deficiency (1)	4q28-q27
(Pre-)amblyopia, susceptibility to (3)	1q43-q43	Severe combined immunodeficiency, HLA class II-negative type (1)	10p13.1
Progressive cone dystrophy (1)	Xp21.1-p11.3	Severe combined immunodeficiency, X-linked 300400 (3)	Xq13
Protein C deficiency (1)	13cen-q13.11	Stem cell leukemia (2)	Xp22.32-33
Protein D deficiency, X-linked (1)	Xp11.4-p11.23	?Stomatitis (2)	6p21.3
Proteinase deficiency, type I or type A type (1)	13q32	Sickle cell anemia (1)	11p15.5
Proteinase deficiency, type II or type B type (1)	3q21-q22	Sjögren-Galabé-Bohmer syndrome (2)	Xcen-q21.3
Protein C deficiency (1)	2q13-q14	Sinus bradycardia (2)	14q32
Protein C inhibitor deficiency (2)	14q32.1	?SLE (1)	16p13
Protein S deficiency (1)	3p11.1-q11.2	Small-cell cancer of lung (2)	3p23-p21
Protoporphyrin, erythropoietic (1)	10pter-p11.21	?Smith-Lemli-Opitz syndrome (2)	7q34-qter
Pseudohermaphroditism, male with gynecomastia (1)	17q11-q12	Smith-Magenis syndrome (2)	17p11.2
Pseudohypoparathyroidism (1)	4q31.1	Spastic paraplegia, X-linked, uncommunicated (2)	Xq21-q22
Pseudohypoparathyroidism, type Ia (1)	20q13.2	Spherocytosis, hereditary (2)	17q21-q22
Pseudotumoral paraneoplastic lymphoma (1)	Chr.2	Spherocytosis, hereditary, Japanese type (1)	13q15
Pseudo-vitamin D dependent rickets 1 (2)	12q14	Spherocytosis, recessive (1)	1q21
Pseudo-Zellweger syndrome (1)	3p23-p22	Spherocytosis-1 (3)	14q22-q23.2
?Pyridoxine dependency with seizures (1)	2q31	Spherocytosis-2 (3)	3p11.2
Pyropoikilocytosis (1)	1q21	Spinal and bulbar muscular atrophy of Kennedy, 313300 (3)	Xcen-q22
Pyruvate carboxylase deficiency (1)	11q	Spinal muscular atrophy II (2)	5q12.2-q13.3
Pyruvate dehydrogenase deficiency (1)	Xp22.3-p22.1	Spinal muscular atrophy III (2)	5q12.2-q13.3
?Rabson-Mendenhall syndrome (1)	19p13.2	Spontaneous abortion, 1 (2)	6p21.3-p21.2
?Ragweed sensitivity (1)	8p21.3	Spontaneous abortion, 2 (2)	12q24
Reifenstein syndrome (1)	Xcen-q22	Spontaneous abortion, 3 (2)	Xq25
Renal cell carcinoma (2)	3p14.2	Spontaneous abortion, 4 (2)	12q13.1-q13.2
Renal glucosuria (2)	6p21.3	Spontaneous abortion, 5 (2)	Xp22
Renal tubular acidosis-osteopetrosis syndrome (1)	4q22	Spontaneous abortion, 6 (2)	5q33-q35
?Renal cone dystrophy (1)	6q25-q26		
?Renal cone rod dystrophy (1)	19q21-q22.2		
Retinitis pigmentosa, autosomal dominant (1)	11p13		

Disorder	Location	Disorder	Location
Stickler syndrome (3)	12q13.11-q13.2	Usher syndrome, type 1C (2)	11p
Sucrose intolerance (1)	3q25-q28	Usher syndrome, type 2 (2)	1q32
Supravalvular aortic stenosis (3)	7q11.2	van der Woude syndrome (2)	1q32
Tay-Sachs disease (1)	15q23-q24	Velocardiofacial syndrome (2)	22q11
Testicular feminization (1)	1cen-q22	Vitreo-retinopathy, exudative, familial (2)	11q13-q23
Thalassemias, alpha- (1)	16pter-p13.3	Vitreo-retinopathy, neovascular inflammatory (2)	11q13
Thalassemias, beta- (1)	11p15.5	[Vivax malaria, susceptibility to] (1)	1q21-q22
Thrombocytopenia, X-linked (2)	Xp21-p11	von Hippel-Lindau syndrome (2)	3p26-p25
Thrombophilia due to elevated HPG (1)	3p14-qter	von Willebrand disease (1)	12pter-p12
Thrombophilia due to excessive plasminogen activator inhibitor (1)	7q21.3-q22	Waardenburg syndrome, type I (3)	2q35
Thrombophilia due to heparin cofactor II deficiency (1)	22q11	Waardenburg syndrome, type III, 48820 (3)	2q35
Thyroid hormone resistance, 274300, 188570 (3)	3p24.3	Waisman parkinsonism-mental retardation syndrome (2)	Xq26
Thyroid iodine peroxidase deficiency (1)	5p13	Watson syndrome, 193520 (3)	17q11.2
Thyroid papillary carcinoma (1)	10q11-q12	Werdnig-Hoffmann disease (2)	5q12.2-q13.3
Thyrotropin-releasing hormone deficiency (1)	Chr.3	Werner syndrome (2)	8p12-p11
Torsion dystonia (2)	9q32-q34	(Wernicke-Korsakoff syndrome, susceptibility to) (1)	3p14.3
Torsion dystonia-parkinsonism, Filipino type (2)	Xq12-q11.1	Wizack-Wolff syndrome (2)	Xq13-q21
Tourette syndrome (2)	18q22.1	William-Beuren syndrome (2)	4q32-q35.1
Transcobalamin II deficiency (1)	22q11.2-qter	Wilms tumor (2)	11p15
[Transcorin deficiency] (1)	14q32.1	Wilms tumor, type 2 (2)	11p15.5
Tracheo Collaris mandibulofacial dysostosis (2)	5q32-q33.1	Wilson disease (2)	13q14-q21
Trichorhinophalangeal syndrome, type I (2)	8q24.12	Wiskott-Aldrich syndrome (2)	Xp11.3-p11.2
Trypsinogen deficiency (1)	7q32-qter	Wolf-Hirschhorn syndrome, 194190 (3)	4p16.1
[Tuberculosis, susceptibility to] (2)	2q	Wolf-Hirschhorn syndrome (2)	4p16.3
Tuberous sclerosis-1 (2)	9q33-q34	Wolman disease (1)	10q24-q25
Tuberous sclerosis-2 (2)	11q23	Wrinkly skin syndrome (2)	2q32
Tuberous sclerosis-3 (2)	12q23.3	Xeroderma pigmentosum (1)	1q42
Tuberous sclerosis-4 (2)	16p13	Xeroderma pigmentosum, group B (3)	2q21
Turner syndrome (1)	Xq13.1	Xeroderma pigmentosum, complementation group C (2)	Chr.5
Tyrosinemia, type I (1)	15q23-q25	Xeroderma pigmentosum, group D, 278730 (1)	19q13.2-q13.3
Tyrosinemia, type II (1)	16q22.1-q22.3	Xeroderma pigmentosum, type A (1)	9q34.1
Urate oxidase deficiency (1)	1p22	Xeroderma pigmentosum, type F (2)	Chr.15
Urolithiasis, 2,8-dihydroxyadenine (1)	16q24	Zellweger syndrome, type II (1)	1p22-p21
Usher syndrome, type IA (2)	14q32	Zellweger syndrome-I (2)	7q11.23
Usher syndrome, type IB (2)	11q13.5		

(reprinted from Culver, K.W., "Gene Therapy", 1994, p. 93, Mary Ann Liebert, Inc., Publishers, New York, NY).

Alternatively tolerogenic conjugates may be submitted in accordance with United States Patent No. 5,358,710 to Sehon et al., incorporated herein by reference in its entirety. Thus the present invention can readily be adapted to any gene therapy protocol and is generally applicable to the administration of any therapeutic immunogenic material and not just the specific examples listed above.

Gene therapy according to the existing art may be applied to somatic cells or germ line cells by methods known such as gold electroporation, microinjection or jet injection, or other methods as set forth in Sambrook et al. "Molecular Cloning: A Laboratory Manual," Cold Spring Harbor Press (1989)" incorporated herein by reference in its entirety.

Thus the invention provides for a method for treating by gene therapy a mammal with a therapeutic amount of a biologically active antigenic material or its expression product. To retain the effectiveness of said antigenic material(s) from counteraction by an antibody(ies) produced against it(them); it is essential to suppress the capacity of the recipient of the gene to mount an antibody response(s) to said biologically active antigenic material(s). This method comprises:

(a) selecting a mammal which has not received prior exposure to said biologically active antigenic material(s);

(b) administering to said mammal in step (a) an immunosuppressive effective amount of a tolerogenic covalent conjugate of said biologically active antigenic material, or an immunogenic fragment thereof, covalently bound to monomethoxypolyethylene glycol of a molecular

weight of about 2000 to 10,000, wherein said poly(ethylene glycol) is monomethoxypolyethylene glycol and said method suppresses the formation of about 98% of antibodies against said antigenic genetic material or its product, the effective amount of said conjugate suppressing in said mammal the formation of immunoglobulin antibodies against the antigenic genetic material(s); and subsequently

(c) administering to said mammal a therapeutically effective amount of said biologically active antigenic genetic material alone, or a derivative thereof synthesized by conjugating to said antigenic genetic material the DNA expressing biologically or pharmacologically active molecules, wherein said tolerogenic conjugate of step (b) is administered at least one day prior to said antigenic genetic material of step (c). The effective dosage for mammals may vary due to such factors as age, weight, activity level or condition of the subject being treated. The effective dosage for animals and humans may be calculated on the basis of the subject's weight.

In an alternative embodiment, the invention provides a method for suppressing the capacity of a mammal to mount an IgG class antibody response to a biologically active antigenic product of genetic material comprising:

(a) selecting a mammal which has not received prior exposure to said biologically active antigenic genetic material;

(b) administering to said mammal of step (a), a tolerogenic covalent conjugate comprising said biologically active antigenic genetic material or an immunogenic fragment thereof, covalently bound to monomethoxypoly(ethylene glycol) of a molecular weight of about 4,500 to 10,000, in an immunosuppressive effective amount capable of suppressing the formation of

immunoglobulin antibodies of the IgG immunoglobulin class against said antigenic genetic material; and subsequently

(c) administering to said mammal a therapeutically effective amount of said biologically active antigenic genetic material alone or an immunogenic derivative of said genetic material, wherein said mammal is suppressed from mounting an IgG class antibody response to said biologically active antigenic genetic material or immunogenic derivative thereof, wherein said tolerogenic conjugate of step (b) is administered at least one day prior to said antigenic protein of step (c).

Similarly the invention provides a method for suppressing the capacity of a mammal to mount an immune response to a biologically active antigenic protein comprising:

(a) selecting a mammal which has not received prior exposure to said biologically active antigenic protein;

(b) administering to said mammal of step (a), a tolerogenic covalent conjugate comprising said biologically active antigenic protein or an antigenic fragment thereof, covalently bound to monomethoxy poly(ethylene glycol) of a molecular weight of 2000 to 10,000, in an immunosuppressive effective amount capable of suppressing an immune response against said antigenic protein; and subsequently

(c) administering to said mammal a therapeutically effective amount of said biologically active antigenic protein alone or an antigenic fragment of said protein, wherein said mammal is suppressed from mounting an immune response to said biologically active antigenic protein or antigenic fragment thereof.

Additionally a method for suppressing the capacity of a mammal's IgG class antibody mediated immune response to a biologically active antigenic protein comprising:

(a) selecting a mammal which has not received prior

exposure to said biologically active antigenic protein;

(b) administering to said mammal of step (a), a tolerogenic covalent conjugate comprising said biologically active antigenic protein or an antigenic fragment thereof, covalently bound to monomethoxy poly(ethylene glycol) of a molecular weight of 2000 to 10,000, in an immunosuppressive effective amount capable of suppressing the formation of immunoglobulin antibodies of the IgG immunoglobulin class against said antigenic protein; and subsequently

(c) administering to said mammal a therapeutically effective amount of said biologically active antigenic protein alone or an antigenic fragment of said protein, wherein said mammal is suppressed from mounting an IgG class antibody response to said biologically active antigenic protein or antigenic fragment thereof, wherein said tolerogenic conjugate of step (b) is administered at least one day prior to said antigenic protein or antigenic fragment thereof of step (c), is provided for by the invention.

In a preferred embodiment the tolerogenic conjugate is administered 0-7 days prior to administration of said antigenic protein. Generally, the tolerogenic conjugate need only be administered at some time prior to administration of the antigenic protein. The administration of the tolerogenic covalent conjugate may be repeated in a preferred embodiment of the invention.

Advantageously the invention also provides a method of preparing an animal for gene therapy comprising

(a) selecting a mammal which has not received prior exposure to a gene therapy biologically active antigenic protein;

(b) administering to said mammal of step (a), a tolerogenic covalent conjugate comprising said gene therapy biologically active antigenic protein or an

antigenic fragment thereof, covalently bound to monomethoxy poly(ethylene glycol) of a molecular weight of 2000 to 10,000, in an immunosuppressive effective amount capable of suppressing an immune response against said gene therapy antigenic protein, wherein said mammal is suppressed from mounting an immune response to a gene therapy biologically active antigenic protein or antigenic fragment thereof.

The invention provides a composition for performing gene therapy comprising a tolerogenic covalent conjugate comprising a gene therapy biologically active antigenic protein or an antigenic fragment thereof, covalently bound to monomethoxy poly(ethylene glycol) of a molecular weight of 2000 to 10,000, in an immunosuppressive effective amount capable of suppressing an immune response against said gene therapy antigenic protein. In a preferred embodiment the composition does not comprise an immunological adjuvant.

In a preferred embodiment the invention provides a method for suppressing an immune response comprising the steps of

a) administering to a mammal an immunosuppressive effective amount of a tolerogenic conjugate including a therapeutic protein, coupled to monomethoxy-polyethylene glycol having a molecular weight of about 2000-10,000 daltons, at least one day prior to administration of therapeutic protein, wherein said method results in suppression of an immune response and the development of tolerance to said therapeutic protein.

The effective amount of the tolerogenic conjugate is preferably about 50-600 micrograms. The tolerogenic conjugate may comprise about 26 to 53% mPEG.

An immunosuppressive composition comprising a tolerogenic covalent conjugate comprising a biologically active antigenic protein or an antigenic fragment

thereof, covalently bound to monomethoxy poly(ethylene glycol) of a molecular weight of 2000 to 10,000, in an immunosuppressive effective amount capable of suppressing an immune response against said antigenic protein. The degree of conjugation between mPEG and the antigenic protein is selected according to the composition, size and conformation of the antigenic protein, such that the degree of conjugation suppresses an immune response to the tolerogenic conjugate.

The purpose of the above description and examples is to illustrate some embodiments of the present invention without implying any limitation. It will be apparent to those of skill in the art that various modifications and variations may be made to the composition and method of the present invention without departing from the underlying principles or scope of the invention. All patents and publications cited herein are incorporated by reference in their entireties.



## WE CLAIM

1. A method for conducting gene therapy comprising the steps of

5 a) administering to a mammal an immunosuppressive effective amount of a tolerogenic conjugate including genetic material or its product, coupled to monomethoxy-  
polyethylene glycol having a molecular weight of about 2000-35,000 daltons, at least one day prior to  
10 administration of therapeutic genetic material for gene therapy, wherein said method results in suppression of the immune response and the development of tolerance to said therapeutic genetic material or its expressed product.

2. The method of claim 1 wherein said therapeutic genetic material is selected from the group consisting of nucleotides, DNA, RNA, mRNA, and vectors including said  
5 therapeutic genetic material, and mixtures thereof, for the expression of a deficient protein product by the methods of gene therapy.

3. The method of claim 1 wherein the deficient protein is expressed in the host by the use of said vectors including said therapeutic genetic materials  
5 which are selected from the group consisting of Moloney murine leukemia virus vectors, adenovirus vectors with tissue specific promoters, herpes simplex vectors, vaccinia vectors, artificial chromosomes, receptor mediated gene delivery vectors, and mixtures of the above vectors.

4. The method of claim 1 wherein said gene therapy comprises, the administration of a cystic fibrosis transmembrane conductance regulator gene (CFTR) or a low density lipoprotein receptor (LDLr) gene.

5. A method for suppressing the capacity of a mammal to mount an immune response to a biologically active antigenic protein comprising:

5 (a) selecting a mammal which has not received prior exposure to said biologically active antigenic protein;

(b) administering to said mammal of step (a), a tolerogenic covalent conjugate comprising said biologically active antigenic protein or an antigenic fragment thereof, covalently bound to monomethoxy  
10 poly(ethylene glycol) of a molecular weight of 2000 to 10,000, in an immunosuppressive effective amount capable of suppressing an immune response against said antigenic protein; and subsequently

15 (c) administering to said mammal a therapeutically effective amount of said biologically active antigenic protein alone or an antigenic fragment of said protein, wherein said mammal is suppressed from mounting an immune response to said biologically active antigenic protein or antigenic fragment thereof.

6. A method for suppressing the capacity of a mammal's IgG class antibody mediated immune response to a biologically active antigenic protein comprising:

5 (a) selecting a mammal which has not received prior exposure to said biologically active antigenic protein;

(b) administering to said mammal of step (a), a tolerogenic covalent conjugate comprising said biologically active antigenic protein or an antigenic fragment thereof, covalently bound to monomethoxy  
10 poly(ethylene glycol) of a molecular weight of 2000 to 35,000, in an immunosuppressive effective amount capable of suppressing the formation of immunoglobulin antibodies of the IgG immunoglobulin class against said antigenic protein; and subsequently

15 (c) administering to said mammal a therapeutically  
effective amount of said biologically active antigenic  
protein alone or an antigenic fragment of said protein,  
wherein said mammal is suppressed from mounting an IgG  
class antibody response to said biologically active  
20 antigenic protein or antigenic fragment thereof, wherein  
said tolerogenic conjugate of step (b) is administered at  
least one day prior to said antigenic protein or  
antigenic fragment thereof of step (c).

7. The method of claim 6, wherein said tolerogenic  
conjugate is administered 7 days prior to administration  
of said antigenic protein.

8. The method of claim 6, further comprising,  
repeating the administration of said tolerogenic covalent  
conjugate.

9. A method of preparing an animal for gene therapy  
comprising

(a) selecting a mammal which has not received prior  
exposure to a gene therapy biologically active antigenic  
5 protein;

(b) administering to said mammal of step (a), a  
tolerogenic covalent conjugate comprising said gene  
therapy biologically active antigenic protein or an  
antigenic fragment thereof, covalently bound to  
10 monomethoxy poly(ethylene glycol) of a molecular weight  
of 2000 to 10,000, in an immunosuppressive effective  
amount capable of suppressing an immune response against  
said gene therapy antigenic protein, wherein said mammal  
is suppressed from mounting an immune response to a gene  
15 therapy biologically active antigenic protein or  
antigenic fragment thereof.

10. A gene therapy composition comprising a tolerogenic covalent conjugate comprising a gene therapy biologically active antigenic protein or an antigenic fragment thereof, covalently bound to monomethoxy poly(ethylene glycol) of a molecular weight of 2000 to 10,000, in an immunosuppressive effective amount capable of suppressing an immune response against said gene therapy antigenic protein.

11. A composition according to claim 10, wherein said composition does not comprise an immunological adjuvant.

12. A method for suppressing an immune response comprising the steps of

a) administering to a mammal an immunosuppressive effective amount of a tolerogenic conjugate including a therapeutic protein, coupled to monomethoxy-polyethylene glycol having a molecular weight of about 2000-10,000 daltons, at least one day prior to administration of therapeutic protein, wherein said method results in suppression of an immune response and the development of tolerance to said therapeutic protein.

13. The method of claim 12, wherein said tolerogenic conjugate comprises about 26 to 53% mPEG.

14. An immunosuppressive composition comprising a tolerogenic covalent conjugate comprising a biologically active antigenic protein or an antigenic fragment thereof, covalently bound to monomethoxy poly(ethylene glycol) of a molecular weight of 2000 to 10,000, in an immunosuppressive effective amount capable of suppressing an immune response against said antigenic protein.

15. A composition according to claim 14, wherein the ratio of the mPEG to antigenic protein is about 3-12 mPEG to one antigenic protein.

16. A composition according to claim 10, wherein the ratio of the mPEG to antigenic protein is about 3-12 mPEG to one antigenic protein.

17. A composition according to claim 14, wherein the ratio of the mPEG to antigenic protein is about 30-50 mPEG to one antigenic protein.

18. A composition according to claim 10, wherein the ratio of the mPEG to antigenic protein is about 30-50 mPEG to one antigenic protein.

5 19. A composition according to claim 10, wherein the degree of conjugation between mPEG and said antigenic protein is selected according to the composition, size and conformation of the antigenic protein, such that said degree of conjugation suppresses an immune response to the tolerogenic conjugate.

FIGURE 1




FIGURE 2





FIGURE 3



# INTERNATIONAL SEARCH REPORT

International Application No

PC1/1B 95/00995

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K48/00 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB,A,2 238 959 (A.SEHON ET AL.) 19 June 1991 cited in the application see page 5, line 22 - page 11, line 14 ---	5-8, 10-19
X	WO,A,93 12145 (BAYLOR COLLEGE OF MEDECINE) 24 June 1993 see page 26, line 30 - page 28, line 18 ---	5-8, 11-14
A	FASEB JOURNAL FOR EXPERIMENTAL BIOLOGY, vol. 6, July 1992 BETHESDA, MD US, pages 2836-2842, R.P.VEMURU ET AL. 'Immune tolerance to a defined heterologous antigen after intrasplenic hepatocyte transplantation: implications for gene therapy' see page 2836 --- -/-	1-4,9

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \* 'A' document defining the general state of the art which is not considered to be of particular relevance
- \* 'E' earlier document but published on or after the international filing date
- \* 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* 'O' document referring to an oral disclosure, use, exhibition or other means
- \* 'P' document published prior to the international filing date but later than the priority date claimed

- \* 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \* 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \* 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* 'a' document member of the same patent family

Date of the actual completion of the international search

28 February 1996

Date of mailing of the international search report

25.03.96

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Cupido, M



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 95/00995

## C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,94 16065 (EXEMPLAR CORPORATION) 21 July 1994 see page 2	1-4,9
A	<p>---</p> <p>SCIENCE, vol. 254, 20 December 1991 LANCASTER, PA US, pages 1802-1805, J.R.CHOWDHURY ET AL. 'Long-term improvement of hypercholesterolemia after ex vivo therapy in LDLR-deficient rabbits.' see page 1804, last paragraph</p> <p>-----</p>	1-4,9

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 95/00995-

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-9, 12, 13  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 1-9, 12 and 13 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 95/00995

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A-2238959	19-06-91	US-A- 5358710	25-10-94
WO-A-9312145	24-06-93	AU-B- 3423293	19-07-93
WO-A-9416065	21-07-94	AU-B- 5962694	15-08-94

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**